

Cyclooxygenase Inhibitors and the Antiplatelet Effects

New England Journal of Medicine

345, 1809-1817

DOI: [10.1056/nejmoa003199](https://doi.org/10.1056/nejmoa003199)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Platelet pharmacology. , 2001, , 341-366.		0
2	Acquired disorders of platelet function. , 2001, , 225-241.		1
3	Antipyretic analgesics. , 2001, , 255-271.		0
4	Rational Use of Analgesic and Antiinflammatory Drugs. New England Journal of Medicine, 2001, 345, 1844-1846.	13.9	18
5	Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7130-7135.	3.3	200
6	NSAIDs without a prescription: over-the-counter access, under-counted risks. American Journal of Gastroenterology, 2002, 97, 2159-2161.	0.2	16
7	The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity. Current Medical Research and Opinion, 2002, 18, 503-511.	0.9	82
8	Aspirin Resistance. Circulation, 2002, 106, e200-1; author reply e200-1.	1.6	1
9	Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. New England Journal of Medicine, 2002, 346, 1589-1590.	13.9	8
10	The Role of Inflammation in Atherosclerosis. Seminars in Neurosurgery, 2002, 13, 203-216.	0.0	8
11	Cyclooxygenase-2 inhibitors: promise or peril?. Mediators of Inflammation, 2002, 11, 275-286.	1.4	37
12	Review: studies on the cardiovascular effects of selective COX-2 inhibitors show mixed results. Evidence-Based Medicine, 2002, 7, 49-49.	0.6	3
13	Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. Canadian Journal of Emergency Medicine, 2002, 4, 268-275.	0.5	19
14	Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?. Current Opinion in Rheumatology, 2002, 14, 225-230.	2.0	22
15	Cyclooxygenase-2 and atherosclerosis. Current Opinion in Lipidology, 2002, 13, 497-504.	1.2	42
17	Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance. Thrombosis and Haemostasis, 2002, 88, 711-715.	1.8	140
18	A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke. Drug Safety, 2002, 25, 943-963.	1.4	8
19	The Design of a Randomized, Placebo-Controlled Trial of Celecoxib in Preprostatectomy Men with Clinically Localized Adenocarcinoma of the Prostate. Clinical Prostate Cancer, 2002, 1, 182-187.	2.1	5

#	ARTICLE	IF	CITATIONS
20	Ibuprofen inhibits antiplatelet effects of aspirin?. <i>Reactions Weekly</i> , 2002, &NA;, 4.	0.0	0
21	Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. <i>Expert Opinion on Drug Safety</i> , 2002, 1, 45-52.	1.0	11
22	Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. <i>Trends in Molecular Medicine</i> , 2002, 8, 390-396.	3.5	214
23	Pain management in the hospitalized patient. <i>Medical Clinics of North America</i> , 2002, 86, 771-795.	1.1	14
25	Ibuprofen against Aspirin â€“ you first, please! Thanks go aheadâ€¦. <i>Spectroscopy</i> , 2002, 16, 95-99.	0.8	0
26	The Impact of NSAIDs on the Risk of Coronary Heart Disease. <i>Hospital Pharmacy</i> , 2002, 37, 919-926.	0.4	0
27	Anti-inflammatory effects of aspirin and sodium salicylate. <i>European Journal of Pharmacology</i> , 2002, 447, 1-9.	1.7	292
28	On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. <i>European Journal of Pharmacology</i> , 2002, 453, 167-173.	1.7	9
29	Recent developments in cyclooxygenase inhibition. <i>Prostaglandins and Other Lipid Mediators</i> , 2002, 68-69, 153-164.	1.0	26
30	Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. <i>American Journal of Cardiology</i> , 2002, 89, 26-32.	0.7	104
31	common drug interactions in cardiology. <i>ACC Current Journal Review</i> , 2002, 11, 19-23.	0.1	0
33	The Demographics of Chronic Pain Management. <i>Journal of Pain and Symptom Management</i> , 2002, 24, S10-S17.	0.6	2
34	Aspirin antiplatelet therapy and nonsteroidal antiinflammatory drugs: Comment on the 2002 update of the American College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 3102-3102.	6.7	2
36	The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. <i>Arthritis and Rheumatism</i> , 2002, 47, 349-355.	6.7	63
37	Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. <i>Arthritis and Rheumatism</i> , 2002, 46, 3046-3054.	6.7	85
38	Et tu, acetaminophen?. <i>Arthritis and Rheumatism</i> , 2002, 46, 2831-2835.	6.7	27
40	Do Over-the-counter medications for migraine hinder the physician?. <i>Current Pain and Headache Reports</i> , 2002, 6, 162-167.	1.3	8
41	The Feng Pao Hsii Lecture. <i>APLAR Journal of Rheumatology</i> , 2002, 5, 41-47.	0.2	0

#	ARTICLE	IF	CITATIONS
42	Aspirin resistance and genetic polymorphisms. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 51-58.	1.0	102
43	Crossreacting Drugs and Chemicals. <i>Clinical Reviews in Allergy and Immunology</i> , 2003, 24, 149-158.	2.9	17
44	Cyclooxygenase-2 Inhibitors. <i>Anesthesia and Analgesia</i> , 2003, 96, 1720-1738.	1.1	69
45	Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. <i>Inflammopharmacology</i> , 2003, 11, 337-354.	1.9	5
46	Bifunctional constructs of aspirin and ibuprofen (non-steroidal anti-inflammatory drugs; NSAIDs) that express antibacterial and alkylation activities. <i>Biotechnology and Applied Biochemistry</i> , 2003, 37, 273.	1.4	6
47	Association Between Bone Mineral Density and the Use of Nonsteroidal Anti-Inflammatory Drugs and Aspirin: Impact of Cyclooxygenase Selectivity. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1795-1802.	3.1	114
48	Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. <i>Canadian Journal of Anaesthesia</i> , 2003, 50, 1004-1008.	0.7	28
49	Antiplatelet therapy in peripheral arterial disease. Consensus statement. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 26, 1-16.	0.8	62
50	NSAIDs and aspirin: friends or foes?. <i>Joint Bone Spine</i> , 2003, 70, 89-90.	0.8	5
51	Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. <i>BMC Cardiovascular Disorders</i> , 2003, 3, 2.	0.7	94
52	Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib**The investigators had full access to the data and complete control over the design, conduct analysis, interpretation, and description of the study. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or in writing the report. The views expressed are those of the investigators alone.. <i>American Journal of Cardiology</i> , 2003, 92, 411-418.	0.7	181
53	Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. <i>Arthritis and Rheumatism</i> , 2003, 48, 12-20.	6.7	110
54	Acetaminophen not associated with gastrointestinal toxicity: Comment on the article by Rahme et al. <i>Arthritis and Rheumatism</i> , 2003, 48, 2074-2075.	6.7	3
57	Aspirin resistance: definition, mechanisms and clinical read-outs. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1710-1713.	1.9	270
58	The platelet P2Y receptors as targets for new antithrombotic drugs. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1133-1135.	1.9	14
60	Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. <i>British Journal of Pharmacology</i> , 2003, 138, 634-641.	2.7	41
61	COX-2 and beyond: approaches to prostaglandin inhibition in human disease. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 879-890.	21.5	439
62	Terapia antitromb�tica y cirug�a. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2003, 10, 71-72.	0.0	0

#	ARTICLE	IF	CITATIONS
63	Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis. <i>Foot and Ankle Clinics</i> , 2003, 8, 187-200.	0.5	1
64	Postprocedure Pain Management of Interventional Radiology Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, 1373-1385.	0.2	24
65	Nonopioid and adjuvant analgesics in chronic pain management: strategies for effective use. <i>Nursing Clinics of North America</i> , 2003, 38, 447-464.	0.7	6
66	Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1747-1753.	1.2	54
67	Pharmacokinetics of Rofecoxib. <i>Clinical Pharmacokinetics</i> , 2003, 42, 545-556.	1.6	25
68	Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. <i>Gastroenterology</i> , 2003, 124, 47-56.	0.6	480
69	Tackling ischaemic heart disease in rheumatoid arthritis. <i>British Journal of Rheumatology</i> , 2003, 42, 607-613.	2.5	143
70	Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. <i>Thrombosis Research</i> , 2003, 111, 165-170.	0.8	66
71	Inflammation in atherosclerosis: causal or casual? The need for randomized trials. <i>American Heart Journal</i> , 2003, 146, 199-202.	1.2	2
72	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. <i>American Heart Journal</i> , 2003, 146, 591-604.	1.2	122
73	Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. <i>Thrombosis Research</i> , 2003, 110, 281-286.	0.8	62
74	Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet, The</i> , 2003, 361, 573-574.	6.3	422
75	Parsing an enigma: the pharmacodynamics of aspirin resistance. <i>Lancet, The</i> , 2003, 361, 542-544.	6.3	72
76	Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet, The</i> , 2003, 361, 1559.	6.3	1
77	Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet, The</i> , 2003, 361, 1560.	6.3	3
78	Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet, The</i> , 2003, 361, 1560-1561.	6.3	2
79	Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet, The</i> , 2003, 361, 1561.	6.3	1
80	COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred. <i>Arthritis Research</i> , 2003, 5, 116.	2.0	4

#	ARTICLE	IF	CITATIONS
81	COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. <i>Arthritis Research</i> , 2003, 5, 28.	2.0	14
82	Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease. <i>Drugs and Aging</i> , 2003, 20, 585-595.	1.3	6
83	Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 265-284.	0.9	44
84	Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 573-585.	1.0	69
85	Potential Cardiovascular Effects of COX-2 Selective Nonsteroidal Antiinflammatory Drugs. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2003, 17, 27-50.	0.5	5
86	Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs. <i>Circulation</i> , 2003, 108, 1191-1195.	1.6	253
87	Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation. <i>Circulation</i> , 2003, 107, 32-37.	1.6	656
88	Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs. <i>Circulation</i> , 2003, 108, 910-911.	1.6	35
89	Management of inflammatory arthritis in the older person. <i>Reviews in Clinical Gerontology</i> , 2003, 13, 283-296.	0.5	2
90	Sleep Duration and Disease. <i>Archives of Internal Medicine</i> , 2003, 163, 1374.	4.3	1
91	Key questions concerning paracetamol and NSAIDs for OA. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 287-287.	0.5	0
92	Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly. <i>Archives of Internal Medicine</i> , 2003, 163, 481.	4.3	242
93	Dental management considerations for the patient with an acquired coagulopathy. Part 2: Coagulopathies from drugs. <i>British Dental Journal</i> , 2003, 195, 495-500.	0.3	84
94	Cost-effectiveness of different postoperative analgesic treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1507-1519.	0.9	4
95	Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. <i>Gut</i> , 2003, 52, 600-608.	6.1	151
96	Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1111-1115.	1.1	35
97	Suppression of Oxidative Stress as a Mechanism of Reduction of Hypercholesterolemic Atherosclerosis by Aspirin. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003, 8, 61-69.	1.0	39
98	Drug-drug interactions involving antiplatelet agents. <i>European Heart Journal</i> , 2003, 24, 1707-1709.	1.0	14

#	ARTICLE	IF	CITATIONS
99	Giving aspirin and ibuprofen after myocardial infarction. <i>BMJ: British Medical Journal</i> , 2003, 327, 1298-1299.	2.4	18
101	Advances in antiplatelet therapy. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 349-363.	1.0	22
102	Gastrointestinal diseases in the elderly. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2003, 6, 41-48.	1.3	29
103	Relationship of Arachidonic Acid Concentration to Cyclooxygenase-Dependent Human Platelet Aggregation. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 983-989.	1.0	15
104	Nonsteroidal Anti-inflammatory Drugs in the Treatment of Pericarditis. <i>Cardiology in Review</i> , 2003, 11, 211-217.	0.6	29
105	Platelets and Anti-platelet Therapy. <i>Journal of Pharmacological Sciences</i> , 2003, 93, 381-396.	1.1	88
106	Anti-inflammatory and antipyretic analgesics and drugs used in gout. <i>Side Effects of Drugs Annual</i> , 2003, 26, 111-130.	0.6	0
107	Cardiac Involvement in Rheumatoid Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, , 121-143.	0.1	1
108	Guidelines for liposomal amphotericin B. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1480-1480.	0.5	2
110	Journal Review. <i>The Consultant Pharmacist</i> , 2004, 19, 445-451.	0.4	0
111	Perspectives and Clinical Significance of Eicosanoids in Immunology, Endocrinology and Metabolic Regulation. , 0, , 227-236.		2
112	Aspirin and Activated Platelets. , 0, , 373-385.		7
113	Medical management of chronic ischemic heart disease. <i>Postgraduate Medicine</i> , 2004, 115, 39-46.	0.9	2
114	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 110, .	1.6	99
115	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2004, , 1107-1128.		0
116	Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?. <i>Cardiovascular Research</i> , 2004, 64, 192-194.	1.8	4
117	For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?. <i>Palliative Medicine</i> , 2004, 18, 275-286.	1.3	27
118	Controversies of Oral Antiplatelet Therapy in Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 649-655.	1.5	5

#	ARTICLE	IF	CITATIONS
119	Rofecoxib, Merck, and the FDA. <i>New England Journal of Medicine</i> , 2004, 351, 2875-2878.	13.9	24
120	Clinical Pharmacology of Novel Selective COX-2 Inhibitors. <i>Current Pharmaceutical Design</i> , 2004, 10, 589-601.	0.9	62
121	Aspirin and coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1175-1181.	1.8	60
122	Throw Away the Aspirin and Take Nonsteroidal Anti-Inflammatory Drugs for the Primary Prevention of Myocardial Infarction. <i>Circulation</i> , 2004, 109, e65-6; author reply e65-6.	1.6	3
123	Antiplatelet Therapy in Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1875.	3.8	35
124	Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. <i>Rheumatology</i> , 2004, 43, 731-736.	0.9	38
125	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 166-181.	1.0	334
126	Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population. <i>Circulation</i> , 2004, 109, 3000-3006.	1.6	197
127	COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin exposed vascular smooth muscle cells. <i>FASEB Journal</i> , 2004, 18, 757-759.	0.2	43
128	Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users. <i>Archives of Internal Medicine</i> , 2004, 164, 1243.	4.3	29
129	The molecular and biological basis for COX-2 selectivity. , 2004, , 41-65.		0
130	COX-2 and the cardiovascular system. , 2004, , 161-178.		0
131	Aspirin and Clopidogrel. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1980-1987.	1.1	395
132	Renal Cyclooxygenase-2 (Cox-2). <i>Kidney and Blood Pressure Research</i> , 2004, 27, 43-62.	0.9	38
133	Aspirin, NSAIDs, Risk of Dementia, and Influence of the Apolipoprotein E Epsilon 4 Allele in an Elderly Population. <i>Neuroepidemiology</i> , 2004, 23, 135-143.	1.1	65
134	Acetylsalicylic Acid and Acetaminophen to Combat Elevated Body Temperature in Acute Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2004, 17, 118-122.	0.8	30
135	Measurement of the Antiplatelet Effects of Aspirin in Cerebrovascular Disease. <i>Stroke</i> , 2004, 35, e146-7; author reply e146-7.	1.0	3
136	Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. <i>Pediatrics</i> , 2004, 114, 1708-1733.	1.0	1,163

#	ARTICLE	IF	CITATIONS
137	Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. <i>Circulation</i> , 2004, 109, 166-171.	1.6	449
138	Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease. <i>Circulation</i> , 2004, 110, 2747-2771.	1.6	1,624
139	Terms and Conditions. <i>Circulation</i> , 2004, 110, 1706-1708.	1.6	62
141	Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2004, 26, 694-700.	0.6	41
142	Antiplatelet agents. <i>The Hematology Journal</i> , 2004, 5, S170-S174.	2.0	9
143	Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDs. <i>Age and Ageing</i> , 2004, 33, 100-104.	0.7	17
144	Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1051-1061.	1.9	124
145	Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 559-563.	1.0	22
147	Anticoagulation in the acute and long-term management of Kawasaki disease. <i>Progress in Pediatric Cardiology</i> , 2004, 19, 179-188.	0.2	10
149	Patient-Specific Antiplatelet Therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 17, 63-77.	1.0	2
150	Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 489-501.	0.8	15
151	Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: Possible interactions and implications for treatment of rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 351-356.	2.1	12
152	Efficiency of the cross-over design: an empirical estimation. <i>Statistics in Medicine</i> , 2004, 23, 3773-3780.	0.8	36
153	The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?. <i>Thrombosis Journal</i> , 2004, 2, 1.	0.9	89
154	Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. <i>FASEB Journal</i> , 2004, 18, 790-804.	0.2	532
155	Accelerated atherosclerosis in inflammatory rheumatic diseases. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 281-292.	0.6	48
156	Failure of Aspirin to Prevent Atherothrombosis. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 57-67.	1.0	27
157	Antiplatelet Agents for the Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 87-106.	1.0	27

#	ARTICLE	IF	CITATIONS
160	The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. <i>Journal of the American College of Cardiology</i> , 2004, 43, 985-990.	1.2	115
161	Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk. <i>Journal of the American College of Cardiology</i> , 2004, 43, 519-525.	1.2	116
164	Co-Administration of Nitric Oxide-Aspirin (NCX-4016) and Aspirin Prevents Platelet and Monocyte Activation and Protects Against Gastric Damage Induced by Aspirin in Humans. <i>Journal of the American College of Cardiology</i> , 2004, 44, 635-641.	1.2	45
165	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, E1-E211.	1.2	1,028
166	Selective cyclooxygenase-2 inhibitors: similarities and differences. <i>Scandinavian Journal of Rheumatology</i> , 2004, 33, 1-6.	0.6	124
167	Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis. <i>Drug Safety</i> , 2004, 27, 185-196.	1.4	9
168	Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?. <i>Drug Safety</i> , 2004, 27, 427-456.	1.4	57
169	Valdecoxib. <i>Drugs</i> , 2004, 64, 1231-1261.	4.9	61
170	Nabumetone. <i>Drugs</i> , 2004, 64, 2315-2343.	4.9	70
171	Risk Reduction Strategies in Ischaemic Stroke. <i>Clinical Drug Investigation</i> , 2004, 24, 245-254.	1.1	15
172	Complications of nonopioid pharmacotherapy. <i>Seminars in Pain Medicine</i> , 2004, 2, 220-227.	0.4	0
175	Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. <i>American Journal of Geriatric Pharmacotherapy</i> , 2004, 2, 119-132.	3.0	39
176	First-generation agents: aspirin, heparin and coumarins. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 23-53.	0.7	31
177	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. <i>Lancet</i> , 2004, 364, 675-684.	6.3	473
178	Should People on Aspirin Avoid Ibuprofen?. <i>Cardiology in Review</i> , 2004, 12, 174-176.	0.6	10
179	Acetylsalicylic Acid, Diclofenac, and Lornoxicam, but Not Rofecoxib, Affect Platelet CD 62 Expression. <i>Anesthesia and Analgesia</i> , 2004, 98, 1082-1085.	1.1	16
180	Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 777-784.	1.0	37
181	Antiplatelet Effect of Aspirin in Patients With Cerebrovascular Disease. <i>Stroke</i> , 2004, 35, 175-178.	1.0	180

#	ARTICLE	IF	CITATIONS
182	Prostaglandins. <i>Journal of Clinical Rheumatology</i> , 2004, 10, S12-S17.	0.5	18
183	Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis. <i>American Journal of Therapeutics</i> , 2004, 11, 244-250.	0.5	71
184	COX-2 Selective NSAIDs. <i>American Journal of Nursing</i> , 2004, 104, 55-56.	0.2	0
185	Self-Medication Practices That Alter the Efficacy of Selected Cardiac Medications. <i>Home Healthcare Nurse</i> , 2004, 22, 88-98.	0.4	7
186	Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. <i>Chest</i> , 2004, 126, 234S-264S.	0.4	578
187	Pain Control:COX-2 Selective NSAIDs. <i>American Journal of Nursing</i> , 2004, 104, 52-55.	0.2	8
188	Section 704 of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MPDIMA) Temporarily Suspends the Requirement That Medicare-Approved Home Health Agencies Collect OASIS Data on non-Medicare/non-Medicaid Patients. <i>Home Healthcare Nurse</i> , 2004, 22, 55.	0.4	0
189	Low-Dose Aspirin Interactions. <i>Home Healthcare Nurse</i> , 2004, 22, 54-55.	0.4	0
190	CE Test: Self-Medication Practices That Alter the Efficacy of Selected Cardiac Medications. <i>Home Healthcare Nurse</i> , 2004, 22, 99-100.	0.4	0
191	Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2004, 164, 852.	4.3	68
193	Pharmaceutical Exploitation: Cyclooxygenase and Lipoxygenase Inhibitors. , 0, , 599-612.		0
194	Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1172-1178.	1.0	11
196	Aspirin Resistance. <i>Pathology Patterns Reviews</i> , 2005, 123, S125-S132.	0.4	3
197	A Clinical and Pharmacologic Review of Skeletal Muscle Relaxants for Musculoskeletal Conditions. <i>American Journal of Therapeutics</i> , 2005, 12, 151-171.	0.5	69
198	Current Status of Nonsteroidal Anti-Inflammatory Drugs in Physiatry. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2005, 84, 885-894.	0.7	4
199	Narrative Review: Aspirin Resistance and Its Clinical Implications. <i>Annals of Internal Medicine</i> , 2005, 142, 370.	2.0	135
200	Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (Review). <i>Oncology Reports</i> , 2005, 13, 559.	1.2	139
201	Selecting Nonprescription Analgesics. <i>American Journal of Therapeutics</i> , 2005, 12, 67-79.	0.5	41

#	ARTICLE	IF	CITATIONS
202	Using aspirin to prevent stroke. JAAPA: Official Journal of the American Academy of Physician Assistants, 2005, 18, 55.	0.1	0
203	Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now. Annals of Internal Medicine, 2005, 142, 212.	2.0	40
204	Massive Hemoptysis in Cystic Fibrosis. Chest, 2005, 128, 729-738.	0.4	189
206	Antiplatelet Activity of J78 (2-Chloro-3-[2-bromo, 1-Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 632 Td (4-fluoro-phenyl]-amin... Thromboxane (TX) A2 Receptor Blockade with TXA2 Synthase Inhibition and Suppression of Cytosolic Ca ²⁺ Mobilization. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 214-219.	1.3	32
207	Inflammation and atherosclerosis in rheumatoid arthritis. Expert Reviews in Molecular Medicine, 2005, 7, 1-24.	1.6	99
208	Aspirin resistance. Journal of Thrombosis and Haemostasis, 2005, 3, 1655-1662.	1.9	65
209	Determinants of the interindividual variability in response to antiplatelet drugs. Journal of Thrombosis and Haemostasis, 2005, 3, 1597-1602.	1.9	84
210	Therapeutic approaches in arterial thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 1577-1589.	1.9	74
211	Bioavailability of diclofenac potassium at low doses. British Journal of Clinical Pharmacology, 2005, 59, 80-84.	1.1	52
212	Review article: aspirin, non-steroidal anti-inflammatory drugs and cyclooxygenase-1 sparing agents. Alimentary Pharmacology and Therapeutics Symposium Series, 2005, 1, 2-5.	0.7	1
213	Review article: clinical management of non-steroidal anti-inflammatory drug and cyclooxygenase-2 inhibitor users: a European perspective. Alimentary Pharmacology and Therapeutics Symposium Series, 2005, 1, 6-10.	0.7	0
214	Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations. Alimentary Pharmacology and Therapeutics Symposium Series, 2005, 1, 26-32.	0.7	4
215	The Editor's Roundtable: Cyclooxygenase-2 Inhibitors and Cardiovascular Risk. American Journal of Cardiology, 2005, 96, 1589-1604.	0.7	19
216	Selective nitrosylation induced in vivo by a nitric oxide-donating cyclooxygenase-2 inhibitor: a NObonomic analysis. Free Radical Biology and Medicine, 2005, 39, 1191-1207.	1.3	24
217	Antithrombotic therapy in children. Progress in Pediatric Cardiology, 2005, 21, 31-43.	0.2	4
218	Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists. Seminars in Arthritis and Rheumatism, 2005, 35, 31-37.	1.6	64
219	Diet and Rheumatoid Arthritis: A Review of the Literature. Seminars in Arthritis and Rheumatism, 2005, 35, 77-94.	1.6	121
220	Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Medicine, 2005, 3, 17.	2.3	64

#	ARTICLE	IF	CITATIONS
221	Antiplatelet Drug Resistance: Not Ready for Prime Time. <i>Pharmacotherapy</i> , 2005, 25, 1621-1628.	1.2	9
222	Aspirin Resistance: An Evaluation of Current Evidence and Measurement Methods. <i>Pharmacotherapy</i> , 2005, 25, 942-953.	1.2	33
223	Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. <i>Pharmacotherapy</i> , 2005, 25, 503-510.	1.2	56
224	Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. <i>Arthritis and Rheumatism</i> , 2005, 53, 12-17.	6.7	27
225	Aspirin and clopidogrel: Efficacy, treatment, and resistance in coronary artery disease. <i>International Journal of Angiology</i> , 2005, 14, 109-114.	0.2	1
226	Resistance to antiplatelet therapy. <i>Current Cardiology Reports</i> , 2005, 7, 242-248.	1.3	15
227	An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. <i>Current Pain and Headache Reports</i> , 2005, 9, 377-389.	1.3	14
228	Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 285-303.	1.8	70
229	The Variability of Platelet Response to Aspirin and Clopidogrel: Revisiting the Caprie, Cure, Credo, and Match Trials. <i>Baylor University Medical Center Proceedings</i> , 2005, 18, 331-336.	0.2	9
230	The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality. <i>Annals of Internal Medicine</i> , 2005, 143, 615.	2.0	14
231	The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors. <i>Annals of Internal Medicine</i> , 2005, 143, 617.	2.0	1
232	The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors. <i>Annals of Internal Medicine</i> , 2005, 143, 615.	2.0	3
233	Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis. , 2005, , 178-201.		0
234	Prescribing Methadone as an Analgesic. <i>Annals of Internal Medicine</i> , 2005, 143, 620.	2.0	11
235	Noninfectious Causes of Cellulitis. <i>Annals of Internal Medicine</i> , 2005, 143, 614.	2.0	2
236	<i>Cardiobacterium valvarum</i> Endocarditis. <i>Annals of Internal Medicine</i> , 2005, 143, 614.	2.0	2
237	The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality. <i>Annals of Internal Medicine</i> , 2005, 143, 615.	2.0	4
238	ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1398-1405.	0.5	5

#	ARTICLE	IF	CITATIONS
239	Impact of Nonsteroidal Antiinflammatory Drugs on the Cardioprotective Effects of Aspirin. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1073-1079.	0.9	15
240	Aspirin Resistance: Detection, Mechanisms and Clinical Implications. <i>Current Cardiology Reviews</i> , 2005, 1, 203-211.	0.6	2
241	Investigation of platelet glycoprotein IIIa polymorphism using flow cytometry in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 437-440.	0.6	3
242	Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 290-300.	3.3	38
243	Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1331-1337.	1.3	29
244	Disease modification and cardiovascular risk reduction: two sides of the same coin?. <i>Rheumatology</i> , 2005, 44, 1473-1482.	0.9	69
245	Acquired Disorders of Platelet Function. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 403-408.	0.9	45
246	The Cardiovascular Pharmacology of COX-2 Inhibition. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 445-451.	0.9	33
247	Antiinflammatory and antipyretic analgesics and drugs used in gout. <i>Side Effects of Drugs Annual</i> , 2005, , 118-138.	0.6	1
248	Clinical pharmacology of etoricoxib. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 269-282.	1.5	15
249	Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 35-43.	0.9	13
250	Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal?. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 941-951.	0.6	14
251	The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). <i>Circulation</i> , 2005, 111, 1713-1716.	1.6	74
252	The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 742-750.	1.0	62
253	COX-2 inhibition and pain management: a review summary. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 431-442.	1.3	5
254	Pharmacology in Rehabilitation: Nonsteroidal Anti-inflammatory Agents. <i>Journal of Orthopaedic and Sports Physical Therapy</i> , 2005, 35, 356-367.	1.7	14
255	Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. <i>Journal of Clinical Investigation</i> , 2005, 116, 4-15.	3.9	851
256	Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease. <i>Circulation</i> , 2005, 111, e267-71.	1.6	22

#	ARTICLE	IF	CITATIONS
257	Cyclooxygenase Inhibition and Cardiovascular Risk. <i>Circulation</i> , 2005, 112, 759-770.	1.6	237
258	Resistance to antiplatelet drugs: current status and future research. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2027-2045.	0.9	65
259	Life after Vioxx: the clinical implications. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 66	0.2	1
260	Platelets and new antiplatelet drugs. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 465-502.	0.2	8
261	The Coxib NSAIDs: Potential Clinical and Pharmacologic Importance in Veterinary Medicine. <i>Journal of Veterinary Internal Medicine</i> , 2005, 19, 633-643.	0.6	138
262	Time Course and Pattern of Blood Loss With Ibuprofen Treatment in Healthy Subjects. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1075-1082.	2.4	23
263	Oral antiplatelet therapy and percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 3-12.	0.9	3
264	The safety of lumiracoxib when used in the treatment of arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 347-350.	0.9	9
265	Low-Dose Aspirin for the Prevention of Atherothrombosis. <i>New England Journal of Medicine</i> , 2005, 353, 2373-2383.	13.9	1,053
266	Insights from Continued Use of a Novacor Left Ventricular Assist System for a Period of 6 Years. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1444.e17-1444.e19.	0.3	22
267	Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. <i>Clinical Therapeutics</i> , 2005, 27, 185-191.	1.1	41
268	Aspirin response and failure in diabetic patients with cardiovascular disease. <i>Current Opinion in Pharmacology</i> , 2005, 5, 190-197.	1.7	11
269	Cardiovascular hazard and non-steroidal anti-inflammatory drugs. <i>Current Opinion in Pharmacology</i> , 2005, 5, 204-210.	1.7	90
271	Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. <i>Drugs</i> , 2005, 65, 725-732.	4.9	38
272	Aspirin Resistance and Atherothrombotic Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 986-993.	1.2	179
273	Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1295-1301.	1.2	252
275	Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1258-1263.	1.2	205
276	Inhibiteurs du fonctionnement plaquettaire. <i>EMC - Hematologie</i> , 2005, 2, 35-51.	0.1	0

#	ARTICLE	IF	CITATIONS
277	Aspirin resistance in stroke: 2004. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 163-169.	0.3	35
278	Novel Nonsteroidal Antiinflammatory Drugs Possessing a Nitric Oxide Donor Diazen-1-ium-1,2-diolate Moiety: A Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4061-4067.	2.9	103
279	Cyclo-Oxygenase-2 Inhibitors. <i>Drugs and Aging</i> , 2005, 22, 185-200.	1.3	46
280	A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. <i>New England Journal of Medicine</i> , 2005, 352, 1293-1304.	13.9	1,801
282	Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. <i>Arthritis Research and Therapy</i> , 2005, 7, S14.	1.6	68
284	Aspirin Resistance. <i>Drugs and Aging</i> , 2006, 23, 559-567.	1.3	40
285	Celecoxib versus a Non-Selective NSAID Plus Proton-Pump Inhibitor. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2006, 20, 11-32.	0.5	2
286	The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. <i>Current Medical Research and Opinion</i> , 2006, 22, 1239-1248.	0.9	14
287	Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems. <i>Annals of Medicine</i> , 2006, 38, 162-172.	1.5	41
290	Aspirin resistance. <i>Lancet, The</i> , 2006, 367, 606-617.	6.3	503
291	Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. <i>Lancet, The</i> , 2006, 368, 1771-1781.	6.3	458
292	The ever growing story of cyclo-oxygenase inhibition. <i>Lancet, The</i> , 2006, 368, 1745-1747.	6.3	30
293	Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PIA1/2 polymorphism. <i>Platelets</i> , 2006, 17, 163-169.	1.1	37
294	Aspirin and Clopidogrel Resistance. <i>Mayo Clinic Proceedings</i> , 2006, 81, 518-526.	1.4	88
295	Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1082-1089.e4.	2.4	76
296	Antiplatelet Agents and Arterial Thrombosis. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 57-74.	1.0	5
297	Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2. <i>Gastroenterology</i> , 2006, 130, 55-64.	0.6	131
299	Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2584-2591.	1.2	1,242

#	ARTICLE	IF	CITATIONS
300	Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 83-94.	1.0	30
301	Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. <i>American Heart Journal</i> , 2006, 152, 237-245.	1.2	61
302	Comments in Response to "Low-Dose Aspirin Increases Aspirin Resistance in Patients with Coronary Artery Disease". <i>American Journal of Medicine</i> , 2006, 119, 287.	0.6	0
303	Reply to "Comments in response to Low-dose aspirin increases aspirin resistance in patients with coronary artery disease". <i>American Journal of Medicine</i> , 2006, 119, 287-288.	0.6	2
304	Paradoxical Rebound Platelet Activation After Painkillers Cessation: Missing Risk for Vascular Events?. <i>American Journal of Medicine</i> , 2006, 119, 707.e11-707.e16.	0.6	27
305	Aspirin "resistance". <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 171-176.	0.6	12
306	Plaquetas: ainda um alvo terapêutico. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2006, 42, 321-332.	0.3	7
307	Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. <i>Thrombosis and Haemostasis</i> , 2006, 95, 253-259.	1.8	110
309	Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs?. <i>Thrombosis and Haemostasis</i> , 2006, 96, 407-412.	1.8	15
310	Aspirin Resistance: A Review Of Diagnostic Methodology, Mechanisms, and Clinical Utility. <i>Advances in Clinical Chemistry</i> , 2006, 42, 81-110.	1.8	10
311	Diclofenac sodium in the treatment of osteoarthritis. <i>Aging Health</i> , 2006, 2, 179-187.	0.3	1
312	Nonsteroidal Anti-inflammatory Drug Use Is a Significant Cause of Peptic Ulcer Disease in a Tertiary Hospital in Singapore: A Prospective Study. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 795-800.	1.1	26
313	Cyclooxygenase Inhibition and Atherothrombosis. <i>Current Drug Targets</i> , 2006, 7, 1275-1284.	1.0	20
314	Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy. <i>Country Review Ukraine</i> , 2006, 8, G35-G37.	0.8	4
316	Anti-inflammatory therapy and cardiovascular risk: new insights. <i>Future Rheumatology</i> , 2006, 1, 7-10.	0.2	0
317	Aspirin Resistance. <i>Cardiology in Review</i> , 2006, 14, 18-25.	0.6	17
318	The Benefit of Aspirin Chemoprophylaxis for Thromboembolism after Total Knee Arthroplasty. <i>Clinical Orthopaedics and Related Research</i> , 2006, 452, 175-180.	0.7	94
319	Aspirin resistance: is this term meaningful?. <i>Current Opinion in Hematology</i> , 2006, 13, 331-336.	1.2	9

#	ARTICLE	IF	CITATIONS
320	Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Internal Medicine Journal, 2006, 36, 308-319.	0.5	37
321	Paracetamol: New Vistas of an Old Drug. CNS Neuroscience & Therapeutics, 2006, 12, 250-275.	4.0	460
322	Non-Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 266-274.	1.2	194
323	Is there an Interaction between the Cardiovascular Protective Effects of Low-Dose Aspirin and Ibuprofen?. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 275-280.	1.2	29
324	Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective non-steroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology, 2006, 61, 730-737.	1.1	21
325	The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Alimentary Pharmacology and Therapeutics, 2006, 23, 1489-1498.	1.9	44
326	New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clinical Pharmacology and Therapeutics, 2006, 79, 9-19.	2.3	173
327	Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clinical Pharmacology and Therapeutics, 2006, 80, 115-125.	2.3	27
328	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clinical Pharmacology and Therapeutics, 2006, 80, 264-274.	2.3	103
329	Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4. Pharmaceutical Research, 2006, 23, 2691-2708.	1.7	41
330	Possible mechanisms of drug-induced aspirin and clopidogrel resistance. Journal of Thrombosis and Thrombolysis, 2006, 22, 139-150.	1.0	22
331	Aspirin resistance “ does it clinically matter?. Clinical Research in Cardiology, 2006, 95, 505-510.	1.5	9
333	The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs. Clinical Rheumatology, 2006, 25, 123-125.	1.0	8
334	Pain management today“ what have we learned?. Clinical Rheumatology, 2006, 25, 2-8.	1.0	68
335	Coxibes: oÃ1 en sommes-nous?. Douleur Et Analgesie, 2006, 19, 42-46.	0.2	0
336	Herbal, Prescribed, and Over-the-Counter Drug Use in Older Women: Prevalence of Drug Interactions. Geriatric Nursing, 2006, 27, 118-129.	0.9	44
337	Cardiovascular risk andÂrheumatoid arthritis: clinical practice guidelines based onÂpublished evidence andÂexpert opinion. Joint Bone Spine, 2006, 73, 379-387.	0.8	75
339	Clinical Implications of Nonopioid Analgesia for Relief of Mild-to-Moderate Pain in Patients with or at Risk for Cardiovascular Disease. American Journal of Cardiology, 2006, 97, 3-9.	0.7	37

#	ARTICLE	IF	CITATIONS
340	Potential for Drug-Drug Interactions in Patients Taking Analgesics for Mild-to-Moderate Pain and Low-Dose Aspirin for Cardioprotection. <i>American Journal of Cardiology</i> , 2006, 97, 23-29.	0.7	25
341	Aspirin resistance: Truth or dare. , 2006, 112, 733-743.		39
342	Cardiovascular Risks of Cyclooxygenase Inhibition. <i>Pharmacotherapy</i> , 2006, 26, 919-938.	1.2	14
343	Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. <i>Arthritis and Rheumatism</i> , 2006, 54, 1378-1389.	6.7	166
344	Cyclooxygenase-2 Inhibition and Coagulation. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, S15-S20.	0.8	31
345	Expectations From Patients With Rheumatoid Arthritis Regarding COX-2s: Cutting to the Heart of the Matter. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, S55-S59.	0.8	0
346	Guidelines on the management of stable angina pectoris. <i>European Heart Journal</i> , 2006, 27, 2606-2606.	1.0	25
347	Is aspirin resistance valid?. <i>Future Cardiology</i> , 2006, 2, 1-4.	0.5	0
348	Aspirin Resistance: Definitions, Mechanisms, Prevalence, and Clinical Significance. <i>Current Pharmaceutical Design</i> , 2006, 12, 251-258.	0.9	64
349	Antipyretic Analgesics: Nonsteroidal Antiinflammatory Drugs, Selective COX-2 Inhibitors, Paracetamol and Pyrazolinones. , 2007, , 65-93.		36
351	Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. <i>Rheumatology</i> , 2006, 45, 1389-1394.	0.9	42
352	What Price Pain Relief?. <i>Circulation</i> , 2006, 113, 2868-2870.	1.6	15
353	Cardiovascular Risk and Inhibition of Cyclooxygenase. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1633.	3.8	966
354	Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1837-1851.	0.5	43
355	The Aspirin Resistance Controversy. <i>Circulation</i> , 2006, 113, 2865-2867.	1.6	27
356	Influence of aspirin or heparin on platelet function and postoperative blood loss after coronary artery bypass surgery. <i>Perfusion (United Kingdom)</i> , 2006, 21, 61-66.	0.5	10
357	Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. <i>Rheumatology</i> , 2006, 46, 265-272.	0.9	40
358	Response to Letter Regarding Article, "Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events" <i>Circulation</i> , 2006, 114, .	1.6	2

#	ARTICLE	IF	CITATIONS
359	NSAIDs and the risk of myocardial infarction: do they help or harm?. <i>European Heart Journal</i> , 2006, 27, 1635-1636.	1.0	28
360	Aspirin-Resistenz / Aspirin resistance. <i>Das Medizinische Laboratorium</i> , 2006, 30, 302-309.	0.0	2
361	Review: Aspirin and diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 74-82.	0.6	1
362	Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. <i>Circulation</i> , 2006, 113, 2906-2913.	1.6	399
363	Letter by Kurth Regarding Article, "Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events" • <i>Circulation</i> , 2006, 114, e495; author reply e496.	1.6	1
364	Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1643-1655.	1.4	29
365	Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 7-13.	0.5	44
366	Primer: managing NSAID-induced ulcer complications"balancing gastrointestinal and cardiovascular risks. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 563-573.	1.7	67
367	Aspirin and clopidogrel resistance: an emerging clinical entity. <i>European Heart Journal</i> , 2006, 27, 647-654.	1.0	286
368	Differentiation of Cyclooxygenase 1- and "Derived Prostanoids in Mouse Kidney and Aorta. <i>Hypertension</i> , 2006, 48, 323-328.	1.3	78
369	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 29, 277-278.	1.0	190
370	Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 764-770.	0.5	100
371	How to Advise Aspirin Use in Patients Who Need NSAIDs. <i>Current Pharmaceutical Design</i> , 2007, 13, 2248-2260.	0.9	16
372	Aspirin and Clopidogrel Resistance. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 114-120.	0.9	38
373	Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3448-H3455.	1.5	47
374	Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions. <i>Current Vascular Pharmacology</i> , 2007, 5, 135-140.	0.8	2
375	Drug Insight: aspirin resistance"fact or fashion?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 42-50.	3.3	111
376	Self-Medication Practices of Spanish-Speaking Older Adults in Hartford, Connecticut. <i>Hispanic Health Care International</i> , 2007, 5, 169-179.	0.5	14

#	ARTICLE	IF	CITATIONS
379	NSAIDs and cardiovascular disease. <i>Heart</i> , 2007, 94, 395-397.	1.2	18
380	An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. <i>Clinical Medicine and Research</i> , 2007, 5, 19-34.	0.4	416
381	Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 981-986.	0.8	27
382	Essential Polyunsaturated Fatty Acids, Inflammation, Atherosclerosis and Cardiovascular Diseases. <i>Sub-Cellular Biochemistry</i> , 2007, 42, 283-297.	1.0	38
383	Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. <i>Rheumatology</i> , 2007, 46, 435-438.	0.9	73
384	Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events. <i>Archives of Internal Medicine</i> , 2007, 167, 1593.	4.3	373
385	Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. <i>Circulation</i> , 2007, 115, 2196-2207.	1.6	191
386	Cardiovascular Effects of the Cyclooxygenase Inhibitors. <i>Hypertension</i> , 2007, 49, 408-418.	1.3	97
388	Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. <i>Future Rheumatology</i> , 2007, 2, 545-565.	0.2	7
389	Coagulation Management in Pediatric Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2007, 53, 640-645.	0.9	48
390	COX-2 Inhibitors and Cardiovascular Risk. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 470-479.	0.8	276
391	Aspirin resistance: What, why and when?. <i>Thrombosis Research</i> , 2007, 119, 551-554.	0.8	26
392	Aspirin resistance. <i>Thrombosis Research</i> , 2007, 120, 337-346.	0.8	49
393	Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. <i>Thrombosis Research</i> , 2007, 119, 453-459.	0.8	4
394	COX-2 in play at the AHA and the FDA. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 303-307.	4.0	41
395	Recent FDA Warning of the Concomitant Use of Aspirin and Ibuprofen and the Effects on Platelet Aggregation. <i>Preventive Cardiology</i> , 2007, 10, 61-63.	1.1	11
396	Dosing Frequency of Aspirin and Prevention of Heart Attacks and Strokes. <i>American Journal of Medicine</i> , 2007, 120, e5.	0.6	8
397	Adverse drug interactions involving common prescription and over-the-counter analgesic agents. <i>Clinical Therapeutics</i> , 2007, 29, 2477-2497.	1.1	163

#	ARTICLE	IF	CITATIONS
398	Effect of human serum albumin on drug metabolism: Structural evidence of esterase activity of human serum albumin. <i>Journal of Structural Biology</i> , 2007, 157, 348-355.	1.3	184
399	The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. <i>International Journal of Cardiology</i> , 2007, 115, 391-396.	0.8	20
400	Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. <i>Lancet, The</i> , 2007, 369, 465-473.	6.3	220
401	Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. <i>Lancet, The</i> , 2007, 370, 2138-2151.	6.3	145
402	Postoperative Analgesia With Ketorolac Is Associated With Decreased Mortality After Isolated Coronary Artery Bypass Graft Surgery in Patients Already Receiving Aspirin: A Propensity-Matched Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2007, 21, 820-826.	0.6	23
403	The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks. <i>Canadian Journal of Cardiology</i> , 2007, 23, 125-131.	0.8	56
404	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 28, 1598-1660.	1.0	1,699
406	Variable Platelet Response to Aspirin in Patients with Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2007, 24, 43-50.	0.8	33
407	Use of Nonsteroidal Antiinflammatory Drugs. <i>Circulation</i> , 2007, 115, 1634-1642.	1.6	698
408	Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. <i>Blood</i> , 2007, 109, 2285-2292.	0.6	198
409	Relationship between Vitamin D Binding Protein and Aspirin Resistance in Coronary Ischemic Patients: A Proteomic Study. <i>Journal of Proteome Research</i> , 2007, 6, 2481-2487.	1.8	50
410	Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. <i>Current Medical Research and Opinion</i> , 2007, 23, 2259-2268.	0.9	8
411	Human Pharmacology of Naproxen Sodium. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 453-460.	1.3	64
412	Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 552-560.	3.2	46
413	Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 818-828.e5.	2.4	222
414	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. <i>Revista Española De Cardiología</i> , 2007, 60, 1070.e1-1070.e80.	0.6	29
415	Diclofenac Potassium 12.5mg Tablets for Mild to Moderate Pain and Fever. <i>Clinical Drug Investigation</i> , 2007, 27, 163-195.	1.1	53
417	Coxibs and Heart Disease. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1-14.	1.2	74

#	ARTICLE	IF	CITATIONS
418	RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology, 2007, 3, 52-59.	0.3	3
419	Sedation, Analgesia, and Related Topics. , 2007, , 53-70.		3
420	Clinical implications of cyclooxygenase-2 inhibitors. Inflammation and Regeneration, 2007, 27, 552-558.	1.5	5
422	Thromboxane Generation. , 2007, , 565-574.		4
423	Acquired Disorders of Platelet Function. , 2007, , 1051-1076.		5
424	Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. Korean Circulation Journal, 2007, 37, 135.	0.7	7
425	Thrombosis-Embolism. , 2007, , 1-11.		0
428	RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA. Rational Pharmacotherapy in Cardiology, 2007, 3, 11-14.	0.3	0
430	Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 1014-1021.	1.4	28
431	Nonsteroidal anti-inflammatory drugs in cats: a review. Veterinary Anaesthesia and Analgesia, 2007, 34, 228-250.	0.3	168
432	Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 287-292.	0.7	12
433	Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. Journal of Thrombosis and Haemostasis, 2007, 5, 230-237.	1.9	171
434	Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test?. Journal of Thrombosis and Haemostasis, 2007, 5, 1835-1838.	1.9	13
435	Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. Journal of Thrombosis and Haemostasis, 2008, 6, 166-173.	1.9	52
436	Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A2 receptor antagonist. European Journal of Pharmacology, 2007, 570, 38-42.	1.7	35
437	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. American Journal of Cardiology, 2007, 99, S1-S35.	0.7	20
438	Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins and Other Lipid Mediators, 2007, 82, 85-94.	1.0	165
439	Coxibs and NSAIDs – Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis and Cartilage, 2007, 15, 849-856.	0.6	13

#	ARTICLE	IF	CITATIONS
440	Pharmacogenomics of platelet responsiveness to aspirin. <i>Pharmacogenomics</i> , 2007, 8, 1413-1425.	0.6	30
443	The post-NSAID era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. <i>Current Pain and Headache Reports</i> , 2007, 11, 415-422.	1.3	7
444	Kawasaki disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 148-158.	0.4	23
446	Aspirin "Resistance". <i>Herz</i> , 2008, 33, 270-278.	0.4	12
447	Accelerated Thrombotic Occlusion of a Medium-Sized Coronary Aneurysm in Kawasaki Disease by the Inhibitory Effect of Ibuprofen on Aspirin. <i>Pediatric Cardiology</i> , 2008, 29, 153-156.	0.6	15
448	4 Years after withdrawal of rofecoxib: where do we stand today?. <i>Rheumatology International</i> , 2008, 28, 1187-1195.	1.5	21
451	The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. <i>Current Rheumatology Reports</i> , 2008, 10, 49-56.	2.1	17
452	Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. <i>Clinical Rheumatology</i> , 2008, 27, 1191-1194.	1.0	16
453	La terapia farmacologica delle ernie discali. <i>Archivio Di Ortopedia E Reumatologia</i> , 2008, 119, 10-12.	0.0	0
454	OTC analgesics and drug interactions: clinical implications. <i>Osteopathic Medicine and Primary Care</i> , 2008, 2, 2.	0.5	28
455	Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: Comment on the article by Erkan et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 635-636.	6.7	7
456	Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. <i>Arthritis and Rheumatism</i> , 2008, 59, 1097-1104.	6.7	86
457	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. <i>Clinical Cardiology</i> , 2008, 31, 121-127.	0.7	7
458	Rules of engagement: The hospitalist and atherothrombosis. <i>Journal of Hospital Medicine</i> , 2008, 3, S1-S3.	0.7	0
459	Adverse drug interactions in dentistry. <i>Periodontology 2000</i> , 2008, 46, 109-142.	6.3	40
460	An evidence-based update of the use of analgesics in dentistry. <i>Periodontology 2000</i> , 2008, 46, 143-164.	6.3	32
461	Blunting of the Cardiovascular Effect of Aspirin by Ibuprofen: What Is the Evidence?. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 812-812.	2.3	2
462	Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance". <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 812-813.	2.3	3

#	ARTICLE	IF	CITATIONS
463	Clinical Development of TLR Agonists as Adjuvants: "Post-alum Adjuvant" Candidates May Reach Beyond Their Intended Purpose. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 813-814.	2.3	2
464	Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1249-1258.	1.9	18
465	Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. <i>Journal of Internal Medicine</i> , 2008, 264, 481-492.	2.7	36
466	Aspirin Resistance: Disparities and Clinical Implications. <i>Pharmacotherapy</i> , 2008, 28, 999-1018.	1.2	10
467	The Antiplatelet Effect of Six Non-Steroidal Anti-Inflammatory Drugs and Their Pharmacodynamic Interaction With Aspirin in Healthy Volunteers. <i>American Journal of Cardiology</i> , 2008, 101, 1060-1063.	0.7	137
468	Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity. <i>European Journal of Pharmacology</i> , 2008, 583, 148-155.	1.7	30
469	Influence of combinations of acetylsalicylic acid, acetaminophen, and diclofenac on platelet aggregation. <i>European Journal of Pharmacology</i> , 2008, 595, 65-68.	1.7	11
470	Nonsteroidal Anti-Inflammatory Drugs and the Heart: What Is the Danger?. <i>Congestive Heart Failure</i> , 2008, 14, 75-82.	2.0	11
471	COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 165-187.	1.6	97
472	Aspirin nonresponse in patients with arterial causes of ischemic stroke: Considerations in detection and management. <i>Journal of the Neurological Sciences</i> , 2008, 272, 1-7.	0.3	8
473	Population Pharmacodynamic Modelling of Aspirin- and Ibuprofen-Induced Inhibition of Platelet Aggregation in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2008, 47, 129-137.	1.6	37
474	Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. <i>Journal of Translational Medicine</i> , 2008, 6, 46.	1.8	57
475	'Aspirin resistance' or treatment non-compliance: Which is to blame for cardiovascular complications?. <i>Journal of Translational Medicine</i> , 2008, 6, 47.	1.8	26
476	NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future. <i>Gastroenterology</i> , 2008, 134, 1240-1246.	0.6	53
477	Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac. <i>Gastroenterology</i> , 2008, 135, 1517-1525.	0.6	121
478	Clopidogrel and Calcium-Channel Antagonists. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1564-1566.	1.2	7
479	Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1628-1636.	1.2	271
480	The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment. <i>American Journal of Gastroenterology</i> , 2008, 103, 221-227.	0.2	15

#	ARTICLE	IF	CITATIONS
481	Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opinion on Investigational Drugs, 2008, 17, 619-640.	1.9	38
482	Pharmacotherapy of acute orofacial pain. , 2008, , 349-376.		2
483	Intensity of Antiplatelet Therapy in Patients with Acute Coronary Syndromes and Percutaneous Coronary Intervention: the Promise of Prasugrel?. Cardiology Clinics, 2008, 26, 629-637.	0.9	6
484	Antiplatelet drug nonresponsiveness. American Heart Journal, 2008, 155, 591-599.	1.2	52
485	Aspirin, NSAIDs, and Cardiovascular Risk: Is There a Link?. American Journal of Medicine, 2008, 121, e9.	0.6	1
486	Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thrombosis Research, 2008, 121, 527-534.	0.8	156
487	Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thrombosis Research, 2008, 122, 359-365.	0.8	13
488	Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends in Pharmacological Sciences, 2008, 29, 391-397.	4.0	23
489	Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB Journal, 2008, 22, 383-390.	0.2	380
491	Resistencia al Ácido acetilsalicílico y sus repercusiones clínicas. Semergen, 2008, 34, 244-248.	0.2	0
492	Cyclooxygenase-2 Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Cardiovascular Risk. Cardiology Clinics, 2008, 26, 589-601.	0.9	37
493	Antiplatelet Agents and Arterial Thrombosis. Cardiology Clinics, 2008, 26, 189-201.	0.9	9
494	Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2008, 8, 91-112.	1.0	21
495	Efficacy and safety of etoricoxib in the treatment of osteoarthritis. Expert Review of Clinical Pharmacology, 2008, 1, 345-355.	1.3	0
496	Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis. Journal of Clinical Pharmacology, 2008, 48, 117-122.	1.0	58
497	NO donor hybrid compounds as multifunctional therapeutic agents. Expert Opinion on Therapeutic Patents, 2008, 18, 1111-1125.	2.4	3
498	Chapter 64 Antithrombotic agents for stroke prevention. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 94, 1277-1294.	1.0	2
499	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 2008, 30, 426-435.	1.0	192

#	ARTICLE	IF	CITATIONS
500	Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke. Archives of Internal Medicine, 2008, 168, 1219.	4.3	65
501	Nonsteroidal Anti-Inflammatory Drugs. , 2008, , 634-643.		0
502	Aspirin: Promise and Resistance in the New Millennium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, s25-32.	1.1	91
503	Summary. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, s51-2.	1.1	1
504	Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis. Cardiovascular & Hematological Disorders Drug Targets, 2008, 8, 268-277.	0.2	28
505	Antiplatelet Therapy in Early Management of Non-ST-segment Elevation Acute Coronary Syndrome: The 2002 and 2007 Guidelines From North America and Europe. Journal of Cardiovascular Pharmacology, 2008, 51, 425-433.	0.8	4
506	Antiplatelet Drugs. Chest, 2008, 133, 199S-233S.	0.4	478
507	Antithrombotic Therapy in Neonates and Children. Chest, 2008, 133, 887S-968S.	0.4	602
508	Hospitalizations for Upper and Lower GI Events Associated With Traditional NSAIDs and Acetaminophen Among the Elderly in Quebec, Canada. American Journal of Gastroenterology, 2008, 103, 872-882.	0.2	118
509	Acetaminophen inhibits prostanoid synthesis by scavenging the PGHSâ€activator peroxynitrite. FASEB Journal, 2008, 22, 215-224.	0.2	46
510	Tetranor PGDM, an Abundant Urinary Metabolite Reflects Biosynthesis of Prostaglandin D2 in Mice and Humans. Journal of Biological Chemistry, 2008, 283, 1179-1188.	1.6	81
511	Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction?. Nature Clinical Practice Rheumatology, 2008, 4, 182-183.	3.2	6
512	Hypertension in rheumatoid arthritis. Rheumatology, 2008, 47, 1286-1298.	0.9	239
513	Safer NSAID strategies: consensus or contentious?. Rheumatology, 2008, 47, 1265-1266.	0.9	3
515	Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. European Journal of Cardio-thoracic Surgery, 2008, 34, 93-108.	0.6	70
516	Risk-Benefit Perspectives in COX-2 Blockade. Current Drug Safety, 2008, 3, 14-23.	0.3	10
517	The Effect on Comorbidity and Pain in Patients with Osteoarthritis. Journal of Pain and Palliative Care Pharmacotherapy, 2008, 22, 336-348.	0.5	9
518	Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COXâ€2 Versus COXâ€1 in Healthy Subjects. Journal of Clinical Pharmacology, 2008, 48, 745-754.	1.0	39

#	ARTICLE	IF	CITATIONS
519	Secondary Stroke Prevention: From Guidelines to Clinical Practice. Journal of the National Medical Association, 2008, 100, 1125-1137.	0.6	20
520	Clinical Applications of Aspirin. , 0, , 223-365.		0
522	Antiplatelet Therapy in Acute Coronary Syndrome without ST Elevation. , 0, , 143-163.		0
523	Antiplatelet Therapy in Chronic Coronary Artery Disease. , 0, , 178-195.		0
524	Aspirin Response Variability and Resistance. , 0, , 47-58.		0
525	Update on the use of analgesics versus nonsteroidal anti-inflammatory drugs in rheumatic disorders: risks and benefits. Current Opinion in Rheumatology, 2008, 20, 239-245.	2.0	8
526	Resistance To Oral Antiplatelet Agents: Fact Or Fantasy?. Methodist DeBakey Cardiovascular Journal, 2008, 4, 26-29.	0.5	0
527	Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs in High Doses Increases Mortality and Risk of Reinfarction in Patients With Prior Myocardial Infarction. Journal of Cardiovascular Nursing, 2008, 23, 14-19.	0.6	9
528	Coronary Artery Stents: II. Perioperative Considerations and Management. Anesthesia and Analgesia, 2008, 107, 570-590.	1.1	104
529	Cardiovascular effects of cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine, 2008, 7, 29-36.	1.5	10
530	Current and Emerging Treatments for Mild/Moderate Acute Ambulatory Pain. American Journal of Therapeutics, 2008, 15, S12-S16.	0.5	6
533	Cyclooxygenase-2 in Cardiovascular Biology. Clinical Medicine Cardiology, 2008, 2, CMC.S741.	0.1	0
534	Non Steroidal Anti Inflammatory Drugs-An Overview. Journal of Medicine (Bangladesh), 2008, 7, 20-31.	0.1	3
535	Increased platelet sensitivity among individuals with aspirin resistance " Platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thrombosis and Haemostasis, 2008, 100, 83-89.	1.8	23
537	Heart Rate Variability in Patients With Stable Coronary Artery Disease and Aspirin Resistance. International Heart Journal, 2008, 49, 413-422.	0.5	10
538	Signaling Pathways Involved in Sphingosine Kinase Activation and Sphingosine-1-Phosphate Release in Rat Myometrium in Late Pregnancy: Role in the Induction of Cyclooxygenase 2. Endocrinology, 2008, 149, 4669-4679.	1.4	29
539	Analysis of platelet α_2 -adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thrombosis and Haemostasis, 2008, 100, 829-838.	1.8	31
540	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. Vascular Health and Risk Management, 2009, 5, 101.	1.0	11

#	ARTICLE	IF	CITATIONS
543	Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. <i>Drug, Healthcare and Patient Safety</i> , 2009, 1, 47.	1.0	54
544	Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. <i>Diabetes Care</i> , 2009, 32, 531-540.	4.3	115
545	Aspirin Resistance. <i>Advances in Hematology</i> , 2009, 2009, 1-10.	0.6	32
546	Osteoarthritis: An Update on Data Currently Reshaping Practice. <i>Journal of Pharmacy Practice</i> , 2009, 22, 75-85.	0.5	0
547	Cardiovascular Effects of Noncardiovascular Drugs. <i>Circulation</i> , 2009, 120, 1123-1132.	1.6	27
548	Cryptogenic Emboli in Patients with Patent Foramen Ovale or Atrial Septal Defect Associated with the Use of Nonsteroidal Anti-Inflammatory Drugs. <i>Cardiology</i> , 2009, 113, 20-24.	0.6	2
549	Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 147-157.	3.3	23
550	Experimental Study of COX-2 Selective and Traditional Non-steroidal Anti-inflammatory Drugs in Total Hip Replacement. <i>Journal of International Medical Research</i> , 2009, 37, 472-478.	0.4	9
551	Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 155-163.	0.9	121
552	Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure. <i>Archives of Internal Medicine</i> , 2009, 169, 141.	4.3	228
553	Aspirin Resistance. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 141-152.	1.6	69
554	An Evidence-Based Review of the Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs. <i>American Journal of Cardiology</i> , 2009, 103, 1227-1237.	0.7	119
555	Assessment, Mechanisms, and Clinical Implication of Variability in Platelet Response to Aspirin and Clopidogrel Therapy. <i>American Journal of Cardiology</i> , 2009, 104, 227-233.	0.7	101
556	A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. <i>European Journal of Pharmacology</i> , 2009, 609, 96-99.	1.7	22
557	Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 1-14.	0.7	36
558	Combination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy aspirin, clopidogrel, or both?. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, S1-6.	0.7	10
559	Diabetes, vascular complications and antiplatelet therapy: open problems. <i>Acta Diabetologica</i> , 2009, 46, 253-261.	1.2	37
560	Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. <i>Journal of Gastroenterology</i> , 2009, 44, 44-52.	2.3	39

#	ARTICLE	IF	CITATIONS
561	Ibuprofen: pharmacology, efficacy and safety. <i>Inflammopharmacology</i> , 2009, 17, 275-342.	1.9	419
562	Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 11-17.	1.0	21
563	Aspirin resistance: An update. <i>Current Atherosclerosis Reports</i> , 2009, 11, 105-110.	2.0	6
564	Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. <i>Current Rheumatology Reports</i> , 2009, 11, 31-35.	2.1	16
566	Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. <i>Annals of Hematology</i> , 2009, 88, 979-988.	0.8	18
567	A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. <i>Osteopathic Medicine and Primary Care</i> , 2009, 3, 1.	0.5	51
568	Aspirin for primary prevention: do potential benefits outweigh the risks?. <i>Internal Medicine Journal</i> , 2009, 39, 401-407.	0.5	2
569	The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. <i>British Journal of Pharmacology</i> , 2009, 157, 931-934.	2.7	55
570	Antiplatelet "resistance" and "nonresponders": what do these terms really mean?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 11-18.	1.0	7
571	Importance of surface properties of affinity resin for capturing a target protein, Cyclooxygenase-1. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1587-1599.	1.4	6
573	Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. <i>Thrombosis Research</i> , 2009, 124, 96-100.	0.8	36
574	Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. <i>Thrombosis Research</i> , 2009, 124, 6-13.	0.8	48
576	Facts and controversies of aspirin and clopidogrel therapy. <i>American Heart Journal</i> , 2009, 157, 412-422.	1.2	20
577	Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. <i>American Heart Journal</i> , 2009, 158, 695-705.	1.2	13
578	Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. <i>Journal of the American College of Cardiology</i> , 2009, 53, 667-677.	1.2	234
579	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1041-1057.	1.2	92
581	Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies. <i>Drug Safety</i> , 2009, 32, 1017-1039.	1.4	19
582	Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. <i>Nature Reviews Cardiology</i> , 2009, 6, 273-282.	6.1	90

#	ARTICLE	IF	CITATIONS
583	Secondary Stroke Prevention Strategies for the Oldest Patients. <i>Drugs and Aging</i> , 2009, 26, 209-230.	1.3	18
584	Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs. <i>Current Medical Research and Opinion</i> , 2009, 25, 2785-2793.	0.9	30
585	Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. <i>Atherosclerosis</i> , 2009, 202, 84-91.	0.4	46
586	Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 5103.	1.5	43
587	Balancing Risks and Benefits of Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 305-314.	1.0	18
588	NSAIDs in elderly patients with heart failure: stuck between a rock and a hard place?. <i>Ageing Health</i> , 2009, 5, 259-262.	0.3	0
589	Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase Inhibition in the Gastrointestinal Tract: A Trip From Peptic Ulcer to Colon Cancer. <i>American Journal of the Medical Sciences</i> , 2009, 338, 96-106.	0.4	84
590	Complications of Acute Coronary Syndrome. , 2009, , 141-172.		1
591	Drug Interactions in Dentistry. <i>Dental Update</i> , 2009, 36, 458-470.	0.1	6
593	A patient with osteoarthritis and cardiovascular disease presenting with bilateral hip pain: a case report. <i>Cases Journal</i> , 2009, 2, 8823.	0.4	1
594	Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact. <i>Current Pharmaceutical Design</i> , 2009, 15, 1085-1094.	0.9	11
595	Use of Nonsteroidal Anti-Inflammatory Drugs in Patients With Cardiovascular Disease. <i>Cardiology in Review</i> , 2010, 18, 204-212.	0.6	89
596	Nonsteroidal Anti-inflammatory Drug Treatment for Postoperative Pericardial Effusion. <i>Annals of Internal Medicine</i> , 2010, 152, 137.	2.0	34
597	Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 859-894.	1.2	29
599	Acetaminophen and its regioisomer, 3-acetamidophenol interfered with the growth of <i>Escherichia coli</i> O157:H7. <i>Toxicology and Environmental Health Sciences</i> , 2010, 2, 278-283.	1.1	3
601	Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients. <i>Journal of Neurology</i> , 2010, 257, 1788-1797.	1.8	2
602	Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. <i>Advances in Therapy</i> , 2010, 27, 400-411.	1.3	14
603	New Approaches to Stroke Prevention in Atrial Fibrillation. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 261-273.	0.4	4

#	ARTICLE	IF	CITATIONS
604	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. <i>Lancet Neurology</i> , The, 2010, 9, 273-284.	4.9	83
605	Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 294-312.	1.6	245
606	AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2010, 106, 873-884.	0.7	21
607	Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1040-1051.	0.7	26
608	Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. <i>Clinical Therapeutics</i> , 2010, 32, 667-677.	1.1	87
609	Antiplatelet Agents in Acute Coronary Syndromes. <i>Current Problems in Cardiology</i> , 2010, 35, 123-170.	1.1	16
612	Aspirin Resistance in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2010, 12, 714-720.	1.0	15
613	Is severe epistaxis associated with acetylsalicylic acid intake?. <i>Laryngoscope</i> , 2010, 120, 200-207.	1.1	46
614	Antiplatelet drug interactions. <i>Journal of Internal Medicine</i> , 2010, 268, 516-529.	2.7	39
615	Pain Management: Part 1: Managing Acute and Postoperative Dental Pain. <i>Anesthesia Progress</i> , 2010, 57, 67-79.	0.2	122
616	Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. <i>Pharmaceuticals</i> , 2010, 3, 2146-2162.	1.7	157
617	Rational use of nonsteroidal anti-inflammatory drugs and proton pump inhibitors in combination for rheumatic diseases. <i>Orthopedic Research and Reviews</i> , 0, Volume 2, 75-84.	0.7	2
618	Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. <i>Patient Related Outcome Measures</i> , 2010, 2, 7.	0.7	6
619	Pharmacologic Interactions in the CICU. , 2010, , 516-531.		1
620	Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch. <i>Journal of Pain Research</i> , 2010, 3, 223.	0.8	29
621	Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 405-412.	0.2	9
622	Letter by Violi et al Regarding Article, "Association of Cyclooxygenase-1â€œDependent and â€œIndependent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterizationâ€œ. <i>Circulation</i> , 2010, 122, e429; author reply e430.	1.6	0
623	Using pharmacokinetic principles to optimize pain therapy. <i>Nature Reviews Rheumatology</i> , 2010, 6, 589-598.	3.5	24

#	ARTICLE	IF	CITATIONS
624	Thromboxane and the thromboxane receptor in cardiovascular disease. <i>Clinical Lipidology</i> , 2010, 5, 209-219.	0.4	94
625	The Future of Antiplatelet Therapy in Cardiovascular Disease. <i>Annual Review of Medicine</i> , 2010, 61, 49-61.	5.0	24
626	Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. <i>Nature Reviews Cardiology</i> , 2010, 7, 461-467.	6.1	38
627	Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 28-33.	3.3	159
628	Platelet Aggregation Tests Are Affected in Pseudothrombocytopenia: Table 1. <i>Laboratory Medicine</i> , 2010, 41, 483-485.	0.8	2
629	Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel. <i>Journal of NeuroInterventional Surgery</i> , 2010, 2, 44-49.	2.0	28
630	Acetylsalicylic acid enhances purinergic receptor-mediated outward currents in rat megakaryocytes. <i>American Journal of Physiology - Cell Physiology</i> , 2010, 298, C602-C610.	2.1	3
631	Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. <i>European Journal of Anaesthesiology</i> , 2010, 27, 999-1015.	0.7	447
632	Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2. <i>Current Medical Research and Opinion</i> , 2010, 26, 1497-1504.	0.9	10
633	Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?. <i>Current Medicinal Chemistry</i> , 2010, 17, 4578-4586.	1.2	28
634	Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. <i>Colloquium Series on Integrated Systems Physiology From Molecule To Function</i> , 2010, 2, 1-75.	0.3	50
635	Resistance to aspirin: Prevalence, mechanisms of action and association with thromboembolic events. A narrative review. <i>Farmacia Hospitalaria (English Edition)</i> , 2010, 34, 32-43.	0.0	2
636	Identifying and assessing benefit-risk in primary care—a family physician's perspective. <i>Rheumatology</i> , 2010, 49, ii18-ii23.	0.9	2
637	Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 893-903.	1.0	47
638	Antiplatelet therapy and vascular disease: an update. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 249-275.	1.0	16
639	The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2010, 82, 87-95.	1.0	27
640	Hypothesis formulation from subgroup analyses: Nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to aspirin resistance. <i>American Heart Journal</i> , 2010, 159, 744-748.	1.2	35
644	Aspirin and Antiplatelet Agent Resistance. <i>CNS Drugs</i> , 2010, 24, 1027-1040.	2.7	19

#	ARTICLE	IF	CITATIONS
645	EIDOS. Drug Safety, 2010, 33, 15-23.	1.4	35
646	Individual variability of response and non-response to acetyl salicylic acid after cardiac surgery. Platelets, 2010, 21, 610-615.	1.1	8
647	Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy. Expert Opinion on Drug Discovery, 2011, 6, 353-369.	2.5	1
648	A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Annals of the Rheumatic Diseases, 2011, 70, 1534-1541.	0.5	131
649	The resolution of inflammation: the devil in the flask and in the details. FASEB Journal, 2011, 25, 1441-1448.	0.2	171
651	Pharmacogenomic Testing in Current Clinical Practice. , 2011, , .		2
652	Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease. American Journal of Medicine, 2011, 124, 614-620.	0.6	65
653	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2011, 27, S1-S59.	0.8	106
654	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology, 2011, 27, 208-221.	0.8	50
655	Poor aspirin response in diabetic patients presenting with acute coronary syndromes: Results using a near patient test. Thrombosis Research, 2011, 128, 196-199.	0.8	2
656	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology, 2011, 7, 381-402.	0.5	13
657	Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels. Atherosclerosis, 2011, 214, 490-491.	0.4	5
658	Comparative antiplatelet activity of COX1 NSAIDs versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study. Reumatismo, 2011, 56, 89-93.	0.4	10
659	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2011, , 1147-1172.		1
660	Diabetes and Aspirin Resistance. , 2011, , .		2
662	Pooled analysis of clinical trial data evaluating the safety and effectiveness of diclofenac epolamine topical patch 1.3% for the treatment of acute ankle sprain. Open Access Journal of Sports Medicine, 2011, 2, 75.	0.6	7
663	ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID. Rational Pharmacotherapy in Cardiology, 2011, 7, 492-500.	0.3	0
664	Adverse Drug Interactions. Anesthesia Progress, 2011, 58, 31-41.	0.2	30

#	ARTICLE	IF	CITATIONS
665	24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2011, 105, 336-344.	1.8	124
666	Antiplatelet Drugs. <i>Anesthesia and Analgesia</i> , 2011, 112, 292-318.	1.1	179
670	Influence of Nonsteroidal Anti-inflammatory Drugs on the Antiplatelet Effects of Aspirin in Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2011, 34, 233-237.	0.6	10
671	Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit. <i>British Journal of Pharmacology</i> , 2011, 164, 561-569.	2.7	5
672	Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. <i>British Journal of Pharmacology</i> , 2011, 164, 1929-1938.	2.7	32
673	Resistance to aspirin and clopidogrel therapy. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 1-18.	0.7	16
674	Aspirin resistance: Effect of clinical, biochemical and genetic factors. , 2011, 130, 213-225.		90
676	Impact of a Fixed-Dose Combination of Naproxen and Esomeprazole Magnesium on Serum Thromboxane B2 Inhibition by Low-Dose Aspirin Over 5 Days in Healthy Adults: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial. <i>Clinical Therapeutics</i> , 2011, 33, 1883-1893.	1.1	17
677	Ketorolac Improves Graft Patency After Coronary Artery Bypass Grafting: A Propensity-Matched Analysis. <i>Annals of Thoracic Surgery</i> , 2011, 92, 603-609.	0.7	23
678	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
681	Antiplatelet Agents for Stroke Prevention. <i>Neurotherapeutics</i> , 2011, 8, 475-487.	2.1	23
682	Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences. <i>Arthritis and Rheumatism</i> , 2011, 63, 850-859.	6.7	56
683	Enhanced catharanthine biosynthesis through regulation of cyclooxygenase in the cell suspension culture of <i>Catharanthus roseus</i> (L.) G. Don. <i>Process Biochemistry</i> , 2011, 46, 783-787.	1.8	11
684	Cardiovascular Risk Markers and Mechanisms in Targeting the COX Pathway for Colorectal Cancer Prevention. <i>Cancer Prevention Research</i> , 2011, 4, 1145-1148.	0.7	6
685	Managing the adverse effects of nonsteroidal anti-inflammatory drugs. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 605-621.	1.3	82
686	Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use. <i>British Journal of Sports Medicine</i> , 2011, 45, 85-90.	3.1	95
687	Aspirin. <i>Circulation</i> , 2011, 123, 768-778.	1.6	194
688	Antiplatelet resistance in stroke. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 251-263.	1.4	64

#	ARTICLE	IF	CITATIONS
689	Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. <i>PLoS Medicine</i> , 2011, 8, e1001098.	3.9	449
690	Migraine and cardiovascular disease in women and the role of aspirin: Subgroup analyses in the Women's Health Study. <i>Cephalgia</i> , 2011, 31, 1106-1115.	1.8	40
691	Letter by Alla et al Regarding Article, "Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study". <i>Circulation</i> , 2011, 124, e553; author reply e555.	1.6	0
692	Aspirin Resistance. <i>Neurohospitalist, The</i> , 2011, 1, 94-103.	0.3	23
693	Hemoptysis under Diclofenac and Antiplatelet Doses of Aspirin. <i>Pharmacology</i> , 2011, 87, 1-4.	0.9	8
694	The Clinical Relevance of Response Variability to Antiplatelet Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 70-75.	0.9	17
695	Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs. <i>Heart</i> , 2011, 97, 1834-1840.	1.2	12
696	Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. <i>BMJ: British Medical Journal</i> , 2011, 342, d2690-d2690.	2.4	161
697	Reducing NSAID-induced gastrointestinal complications. <i>Drug and Therapeutics Bulletin</i> , 2011, 49, 18-21.	0.3	6
698	Analgesic Efficacy and Safety of the Diclofenac Epolamine Topical Patch 1.3% (DETP) in Minor Soft Tissue Injury. <i>International Journal of Sports Medicine</i> , 2011, 32, 635-643.	0.8	13
699	Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 13-26.	0.2	68
700	Laboratory signs of aspirin response in haemodialysis patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 426-431.	0.6	3
703	Drugs that Affect Platelet Function. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 865-883.	1.5	125
704	Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 4311-4325.	0.9	17
705	Overcoming aspirin treatment failure in diabetes. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 183-198.	2.7	9
706	Guilty by Association: Platelet Reactivity and Inflammation in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 210-211.	1.0	2
707	Application of HPLC for the Simultaneous Determination of Aceclofenac, Paracetamol and Tramadol Hydrochloride in Pharmaceutical Dosage Form. <i>Scientia Pharmaceutica</i> , 2012, 80, 337-351.	0.7	24
708	Aspirin: A History, A Love Story. <i>The Consultant Pharmacist</i> , 2012, 27, 322-329.	0.4	37

#	ARTICLE	IF	CITATIONS
709	Pharmacogenetics of the Antiplatelet Effect of Aspirin. <i>Current Pharmaceutical Design</i> , 2012, 18, 5294-5308.	0.9	37
710	Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5273-5293.	0.9	19
711	Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance. <i>Current Pharmaceutical Design</i> , 2012, 18, 5344-5361.	0.9	59
712	Platelet Turnover in Atherothrombotic Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5328-5343.	0.9	20
714	Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use. <i>Journal of Trauma and Acute Care Surgery</i> , 2012, 72, 1658-1663.	1.1	94
715	Nonsteroidal anti-inflammatory drugs and their effects in the elderly. <i>Aging Health</i> , 2012, 8, 167-177.	0.3	13
716	Antithrombotic Therapy in Neonates and Children. <i>Chest</i> , 2012, 141, e737S-e801S.	0.4	1,229
717	New approaches for measurement of platelet reactivity. <i>Blood</i> , 2012, 119, 3378-3379.	0.6	0
718	Overcoming aspirin resistance in MPN. <i>Blood</i> , 2012, 119, 3377-3378.	0.6	10
719	Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. <i>Cardiovascular Therapeutics</i> , 2012, 30, e41-50.	1.1	6
720	Development of Porous Nanomaterials for Applications in Drug Delivery and Imaging. <i>ACS Symposium Series</i> , 2012, , 239-258.	0.5	11
722	Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. <i>Drug Discovery Today</i> , 2012, 17, 296-309.	3.2	59
723	Development and evaluation of diclofenac sodium thermoreversible subcutaneous drug delivery system. <i>International Journal of Pharmaceutics</i> , 2012, 439, 120-126.	2.6	31
724	Ischemic Stroke in Patients Receiving Aspirin. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 868-872.	0.7	8
725	Paracetamol and cyclooxygenase inhibition: is there a cause for concern?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 20-25.	0.5	94
726	Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1496-1501.	0.5	38
727	Increased Superoxide and Endothelial NO Synthase Uncoupling in Blood Vessels of Bmal1-Knockout Mice. <i>Circulation Research</i> , 2012, 111, 1157-1165.	2.0	103
728	Variability of Platelet Indices and Function: Acquired and Genetic Factors. <i>Handbook of Experimental Pharmacology</i> , 2012, , 395-434.	0.9	14

#	ARTICLE	IF	CITATIONS
729	50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams. <i>Platelets</i> , 2012, 23, 415-422.	1.1	40
730	Aspirin and Other COX-1 Inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2012, , 137-164.	0.9	24
731	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012, 163, 768-776.e2.	1.2	72
732	Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 141-151.	1.0	20
733	<i>Cardiovascular Safety</i> . , 2012, , 141-162.		0
734	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. <i>Drugs</i> , 2012, 72, 2087-2116.	4.9	106
735	New Directions in Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 433-445.	1.4	61
736	Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. <i>American Heart Journal</i> , 2012, 164, 600-606.e1.	1.2	95
737	Drug-Drug Interactions in Cardiovascular Catheterizations and Interventions. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1195-1208.	1.1	12
738	Resistance to antiplatelet treatment: The clinical relevance of platelet function assays. <i>Cor Et Vasa</i> , 2012, 54, e305-e313.	0.1	3
739	Perioperative management of a neurosurgical patient requiring antiplatelet therapy. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1316-1320.	0.8	9
740	Aspirin Loading and Release from MCM-41 Functionalized with Aminopropyl Groups via Co-condensation or Postsynthesis Modification Methods. <i>Journal of Physical Chemistry C</i> , 2012, 116, 18358-18366.	1.5	97
741	Mechanisms of variability in antiplatelet agents response. <i>Thrombosis Research</i> , 2012, 130, S27-S28.	0.8	15
742	Advances in monitoring of aspirin therapy. <i>Platelets</i> , 2012, 23, 526-536.	1.1	35
743	Variability in the response to antiplatelet treatment in diabetes mellitus. <i>Prostaglandins and Other Lipid Mediators</i> , 2012, 98, 48-55.	1.0	7
744	An Experimental and Computational Study of the Loading and Release of Aspirin from Zeolite HY. <i>Journal of Physical Chemistry C</i> , 2012, 116, 21382-21390.	1.5	56
745	<i>Ibuprofen: Pharmacology, Therapeutics and Side Effects</i> . , 2012, , .		29
747	<i>Inflammation and Atherosclerosis</i> . , 2012, , .		6

#	ARTICLE	IF	CITATIONS
748	Drug Interactions. Deutsches Ärztblatt International, 2012, 109, 546-55; quiz 556.	0.6	122
749	Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. Thrombosis, 2012, 2012, 1-11.	1.4	48
750	Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin. Thrombosis, 2012, 2012, 1-1.	1.4	3
751	Do Aspirin and Other Antiplatelet Drugs Reduce the Mortality in Critically Ill Patients?. Thrombosis, 2012, 2012, 1-8.	1.4	51
752	The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Acta Cardiologica, 2012, 67, 445-448.	0.3	35
753	Antiplatelet agents and diabetes. Sang Thrombose Vaisseaux, 2012, 24, 109-118.	0.1	0
754	Identification of Independent Predictive Factors for Atherosclerosis in Rheumatoid Arthritis: Based on KARRA Cohort Study. Journal of Rheumatic Diseases, 2012, 19, 30.	0.4	0
755	Measurements of thromboxane production and their clinical significance in coronary heart disease. Thrombosis and Haemostasis, 2012, 108, 6-8.	1.8	14
756	What Is The ÃSafestÃNon-Steroidal Anti-Inflammatory Drugs?. American Medical Journal, 2012, 3, 115-123.	1.0	21
757	Antiplatelet Drugs. Chest, 2012, 141, e89S-e119S.	0.4	318
758	Room for improvement: unmet needs in postoperative pain management. Expert Review of Neurotherapeutics, 2012, 12, 587-600.	1.4	21
759	Aspirin Resistance: Current Status and Role of Tailored Therapy. Clinical Cardiology, 2012, 35, 673-680.	0.7	51
760	A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International, 2012, 32, 1491-1502.	1.5	301
761	Insights into the binding of the drugs diclofenac sodium and cefotaxime sodium to serum albumin: Calorimetry and spectroscopy. European Journal of Pharmaceutical Sciences, 2012, 46, 435-445.	1.9	48
762	Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 469-474.	0.7	24
763	The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology, 2013, 21, 201-232.	1.9	440
764	Perceived medication use challenges and coping strategies among medical outpatients in Nigeria. International Journal of Clinical Pharmacy, 2013, 35, 65-71.	1.0	2
765	Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. European Journal of Clinical Pharmacology, 2013, 69, 365-371.	0.8	52

#	ARTICLE	IF	CITATIONS
766	Drug-Drug Interactions with Anticoagulants and Antiplatelets. <i>Hospital Medicine Clinics</i> , 2013, 2, e130-e141.	0.2	1
767	Platelet Function Profiles in Patients with Diabetes Mellitus. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 329-345.	1.1	46
768	Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors. <i>Clinical Drug Investigation</i> , 2013, 33, 167-183.	1.1	19
769	Effective, selective and specific inhibition of COX-1 may overcome the 'aspirin paradox'. <i>Thrombosis Research</i> , 2013, 132, 1-2.	0.8	6
770	Aspirin and aspirin resistance in coronary artery disease. <i>Current Opinion in Pharmacology</i> , 2013, 13, 242-250.	1.7	35
771	Soroka acute myocardial infarction (SAMI) score predicting 10-year mortality following acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 3068-3070.	0.8	10
772	Vascular effects of nonsteroidal antiinflammatory drugs. <i>Joint Bone Spine</i> , 2013, 80, 358-362.	0.8	26
774	Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring. , 2013, , 45-112.		6
775	Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. <i>European Journal of Pharmacology</i> , 2013, 721, 215-224.	1.7	69
777	Evaluation of Antiplatelet Agents for Secondary Prevention of Stroke Using Mixed Treatment Comparison Meta-analysis. <i>Clinical Therapeutics</i> , 2013, 35, 1490-1500.e7.	1.1	22
778	Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. <i>International Journal of Cardiology</i> , 2013, 163, 266-271.	0.8	21
779	Mitigating the Cardiovascular and Renal Effects of NSAIDs: Table 1. <i>Pain Medicine</i> , 2013, 14, S23-S28.	0.9	40
780	Cardiovascular Pharmacology Core Reviews. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 505-513.	1.0	12
781	Towards a mechanism-based approach to pain management in osteoarthritis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 654-664.	3.5	242
782	An Alkyne-Aspirin Chemical Reporter for the Detection of Aspirin-Dependent Protein Modification in Living Cells. <i>Journal of the American Chemical Society</i> , 2013, 135, 14568-14573.	6.6	70
783	Synthesis and Chemical and Biological Comparison of Nitroxyl- and Nitric Oxide-Releasing Diazeniumdiolate-Based Aspirin Derivatives. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7804-7820.	2.9	68
784	An update on Kawasaki disease: Clinical features, diagnosis, treatment and outcomes. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, 614-623.	0.4	54
786	Cardiovascular disease and non-steroidal anti-inflammatory drug prescribing in the midst of evolving guidelines. <i>Journal of Evaluation in Clinical Practice</i> , 2013, 19, 1026-1034.	0.9	12

#	ARTICLE	IF	CITATIONS
787	Drug Resistance and Pseudoresistance. <i>Circulation</i> , 2013, 127, 377-385.	1.6	187
788	Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 12-15.	0.7	16
789	<scp>d</scp>-Amino Acids Boost the Selectivity and Confer Supramolecular Hydrogels of a Nonsteroidal Anti-Inflammatory Drug (NSAID). <i>Journal of the American Chemical Society</i> , 2013, 135, 542-545.	6.6	264
790	ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without âœaspirin dilemmaâœ. <i>Thrombosis Research</i> , 2013, 132, 56-62.	0.8	18
791	The efficacy and safety of low intensity warfarin therapy in Chinese elderly atrial fibrillation patients with high CHADS2 risk score. <i>International Journal of Cardiology</i> , 2013, 167, 3067-3068.	0.8	12
792	Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. <i>Cardiovascular Research</i> , 2013, 99, 137-145.	1.8	48
793	Aspirin insensitive thrombophilia: Transcript profiling of blood identifies platelet abnormalities and HLA restriction. <i>Gene</i> , 2013, 520, 131-138.	1.0	10
794	Ibuprofen: from invention to an OTC therapeutic mainstay. <i>International Journal of Clinical Practice</i> , 2013, 67, 9-20.	0.8	45
795	Monitoring of Antiplatelet Therapy. , 2013, , 603-633.		2
796	Acquired Disorders of Platelet Function. , 2013, , 1049-1073.		3
798	Activation of the bile acid receptor <scp>GPBAR</scp>1 protects against gastrointestinal injury caused by nonâœsteroidal antiâœinflammatory drugs and aspirin in mice. <i>British Journal of Pharmacology</i> , 2013, 168, 225-237.	2.7	17
799	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 307-317.	0.6	6
800	Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet, The</i> , 2013, 382, 769-779.	6.3	1,413
801	Opioids for Chronic Pain: New Evidence, New Strategies, Safe Prescribing. <i>American Journal of Medicine</i> , 2013, 126, S3-S11.	0.6	73
802	Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 944-947.	0.6	9
803	Pharmacokinetic considerations for antithrombotic therapies in stroke. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1335-1347.	1.5	4
804	Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease. <i>Circulation</i> , 2013, 128, 2622-2703.	1.6	260
805	Association of COX-2 rs20417 with aspirin resistance. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 95-99.	1.0	33

#	ARTICLE	IF	CITATIONS
806	Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it. JRSM Short Reports, 2013, 4, 1-9.	0.6	6
808	Management of Hyperuricemia and Gout. , 2013, , 291-385.		0
809	Aspirin resistance: Where are we now?. Anatolian Journal of Cardiology, 2013, 13, 370-3.	0.4	6
810	Historical Lessons in Translational Medicine. Circulation Research, 2013, 112, 174-194.	2.0	38
811	Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Therapeutic Advances in Chronic Disease, 2013, 4, 206-222.	1.1	26
812	Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Therapeutic Advances in Musculoskeletal Disease, 2013, 5, 166-181.	1.2	39
813	Is aspirin still the drug of choice for management of patients with peripheral arterial disease?. Vasa - European Journal of Vascular Medicine, 2013, 42, 88-95.	0.6	16
814	High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs â€“ pharmacological mechanisms and clinical relevance. Thrombosis and Haemostasis, 2013, 109, 825-833.	1.8	66
815	Efficacy of aceclofenac and diclofenac sodium for relief of postoperative pain after third molar surgery: A randomised open label comparative study. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 144-145.	0.2	12
816	Aspirin Use in Rheumatoid Arthritis Patients with Increased Risk of Cardiovascular Disease. ISRN Rheumatology, 2013, 2013, 1-4.	1.9	3
817	Advances in Our Understanding of â€œResistanceâ€•to Antiplatelet Agents for Prevention of Ischemic Stroke. Stroke Research and Treatment, 2013, 2013, 1-7.	0.5	11
818	Comparison of the postoperative analgesia of intravenous infusion of adenosine and fentanyl. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 145.	0.2	1
819	Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials. Recent Results in Cancer Research, 2013, 191, 67-93.	1.8	38
820	Necrosis in DU145 prostate cancer spheroids induces COXâ€•2/mPGESâ€•1â€•derived PGE₂ to promote tumor growth and to inhibit T cell activation. International Journal of Cancer, 2013, 133, 1578-1588.	2.3	19
821	Identifying determinants of variability to tailor aspirin therapy. Expert Review of Cardiovascular Therapy, 2013, 11, 365-379.	0.6	23
822	Clinical importance of antiplatelet drugs in cardiovascular diseases. Clinical Hemorheology and Microcirculation, 2013, 53, 81-96.	0.9	24
823	Differential Impact of Inflammation on Six Laboratory Assays Measuring Residual Arachidonic Acid-Inducible Platelet Reactivity During Dual Antiplatelet Therapy. Journal of Atherosclerosis and Thrombosis, 2013, 20, 630-645.	0.9	19
824	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0

#	ARTICLE	IF	CITATIONS
825	TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN. Rational Pharmacotherapy in Cardiology, 2013, 9, 301-305.	0.3	1
826	Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vascular Health and Risk Management, 2014, 10, 25.	1.0	39
827	The Effect of Pre-Injury Anti-Platelet Therapy on the Development of Complications in Isolated Blunt Chest Wall Trauma: A Retrospective Study. PLoS ONE, 2014, 9, e91284.	1.1	13
828	Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 603-610.	0.9	20
829	Activation of platelets by endocannabinoids: Distinct agonists or arachidonate reservoirs?. Platelets, 2014, 25, 463-464.	1.1	1
831	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2014, 12, 1185-1203.	0.6	23
832	Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16830-16835.	3.3	68
833	The use of Latin squares and related block designs in implementation research. Journal of Clinical Epidemiology, 2014, 67, 1299-1301.	2.4	2
834	Variability in the Response to Non-steroidal Anti-inflammatory Drugs: Mechanisms and Perspectives. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 56-63.	1.2	85
835	Prevention and Treatment of NSAID Gastropathy. Current Treatment Options in Gastroenterology, 2014, 12, 398-413.	0.3	22
837	Confirmation of Reported Aspirin Use in Community Studies. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 385-392.	0.7	19
838	COX-1-derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse. Blood, 2014, 124, 1610-1621.	0.6	18
839	Platelets: Still a Therapeutical Target for Haemostatic Disorders. International Journal of Molecular Sciences, 2014, 15, 17901-17919.	1.8	13
840	Antiplatelet effect of acetylsalicylic acid, metamizole and their combination - in vitro and in vivo comparisons. Clinical Hemorheology and Microcirculation, 2014, 56, 1-12.	0.9	10
841	In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygenase inhibitors. European Journal of Pharmacology, 2014, 723, 194-201.	1.7	2
842	Aspirin: An Alternative for Pulmonary Embolism Prophylaxis After Arthroplasty?. Clinical Orthopaedics and Related Research, 2014, 472, 482-488.	0.7	91
843	Mechanisms of aspirin resistance. , 2014, 141, 69-78.		120
844	Prevalence of Nonresponsiveness to Aspirin in Patients with Symptomatic Peripheral Arterial Disease Using True Point of Care Testing. CardioVascular and Interventional Radiology, 2014, 37, 631-638.	0.9	16

#	ARTICLE	IF	CITATIONS
845	High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures. CardioVascular and Interventional Radiology, 2014, 37, 559-571.	0.9	6
846	Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking. Journal of Endocrinological Investigation, 2014, 37, 331-338.	1.8	9
847	The Thrombotic and Arrhythmogenic Risks of Perioperative NSAIDs. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 369-378.	0.6	10
848	Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiology and Drug Safety, 2014, 23, 1128-1138.	0.9	51
849	Safe Prescription Recommendations for Non Steroidal Anti-inflammatory Drugs: Consensus Document Elaborated by Nominated Experts of Three Scientific Associations (SER-SEC-AEG). ReumatologĀa ClĀnica (English Edition), 2014, 10, 68-84.	0.2	9
850	Pharmacotherapeutic agents used in temporomandibular disorders. Oral Diseases, 2014, 20, n/a-n/a.	1.5	6
851	Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opinion on Drug Safety, 2014, 13, 167-179.	1.0	33
852	A review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic risk. Journal of Human Nutrition and Dietetics, 2014, 27, 1-21.	1.3	114
853	Nonsteroidal Anti-inflammatory Drugs, Acetaminophen, and COX-2 Inhibitors. , 2014, , 553-568.e5.		10
854	NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. American Journal of Medicine, 2014, 127, 53-60.e1.	0.6	43
855	Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy. European Journal of Internal Medicine, 2014, 25, 821-825.	1.0	13
857	Antiplatelet Therapy in the Management of Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2014, 9, 319-323.	1.2	6
858	Manganese-mefenamic acid complexes exhibit high lipoxygenase inhibitory activity. Dalton Transactions, 2014, 43, 10930-10939.	1.6	41
859	Modified MCM-41 as a drug delivery system for acetylsalicylic acid. Solid State Sciences, 2014, 38, 85-89.	1.5	21
860	Testing Cardiovascular Drug Safety and Efficacy in Randomized Trials. Circulation Research, 2014, 114, 1156-1161.	2.0	5
861	Natural halloysite nanotubes modified as an aspirin carrier. RSC Advances, 2014, 4, 44197-44202.	1.7	96
865	Recomendaciones para una prescripci3n segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades cientĀficas (SER-SEC-AEG). ReumatologĀa ClĀnica, 2014, 10, 68-84.	0.2	21
866	Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis. Biochemical Pharmacology, 2014, 88, 189-200.	2.0	35

#	ARTICLE	IF	CITATIONS
868	Drug-drug interaction between NSAIDs and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opinion on Drug Safety, 2014, 13, 903-917.	1.0	16
869	Nonsteroidal Anti-Inflammatory Drugs and the Heart. Circulation, 2014, 129, 907-916.	1.6	99
870	Platelet Function Testing in Contemporary Clinical and Interventional Practice. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 300.	0.4	34
871	Involvement of glutamate-cystine/glutamate transporter system in aspirin-induced acute gastric mucosa injury. Biochemical and Biophysical Research Communications, 2014, 450, 135-141.	1.0	9
872	Osteoarthritis. Annals of Internal Medicine, 2014, 161, ITC1-1.	2.0	20
873	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications. Regional Anesthesia and Pain Medicine, 2015, 40, 182-212.	1.1	248
874	Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease. Pharmacotherapy, 2015, 35, 520-535.	1.2	39
875	Platelets at the interface of thrombosis, inflammation, and cancer. Blood, 2015, 126, 582-588.	0.6	465
876	PharmGKB summary. Pharmacogenetics and Genomics, 2015, 25, 416-426.	0.7	243
877	Searching for factors associated with resistance to acetylsalicylic acid used for secondary prevention of stroke. Archives of Medical Science, 2015, 1, 106-114.	0.4	4
878	Pharmacokinetics/pharmacodynamics Analysis of Antiplatelet Effects of Non-steroidal Anti-inflammatory Drugs. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Ovlock 10 Tf 50 337	0.0	0
879	Prevention of dipyron (metamizole) induced inhibition of aspirin antiplatelet effects. Thrombosis and Haemostasis, 2015, 114, 87-95.	1.8	25
880	Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2015, 13, 40-49.	0.4	8
881	Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs. Therapeutics and Clinical Risk Management, 2015, 11, 1061.	0.9	147
882	Treatment of Acute ST-Elevation Myocardial Infarction. Cardiovascular Medicine, 2015, , 505-532.	0.0	0
884	Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects. Journal of Thrombosis and Haemostasis, 2015, 13, S323-S331.	1.9	21
885	NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prevention Research, 2015, 8, 1156-1162.	0.7	74
886	Risk of ischemic stroke associated with non-steroidal anti-inflammatory drugs and paracetamol: a population-based case-control study. Journal of Thrombosis and Haemostasis, 2015, 13, 708-718.	1.9	44

#	ARTICLE	IF	CITATIONS
887	Recurrent Stroke while on Antiplatelet Therapy. <i>Neurologic Clinics</i> , 2015, 33, 475-489.	0.8	15
888	Inhibition of Antiplatelet Effects of Aspirin by Nonopioid Analgesics. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 131-134.	2.3	8
889	Aspirin resistance: Prevalence and clinical outcome in Egypt. <i>Egyptian Journal of Critical Care Medicine</i> , 2015, 3, 23-27.	0.2	1
890	Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. <i>Pharmacological Reports</i> , 2015, 67, 952-958.	1.5	9
891	Pharmacological Treatment of Pain: Future Trends and Novel Insights. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 104-108.	2.3	2
893	Non-steroidal anti-inflammatory drugs and cardiovascular risk: At crossroads. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 736-737.	2.3	0
894	The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 74-85.	1.2	105
895	Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 337-345.	0.8	6
896	A brief review on high on-aspirin residual platelet reactivity. <i>Vascular Pharmacology</i> , 2015, 67-69, 6-9.	1.0	26
897	Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. <i>BMC Medicine</i> , 2015, 13, 55.	2.3	165
898	Antiplatelet drug resistance: Molecular insights and clinical implications. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 21-27.	1.0	32
899	Platelets and diabetes mellitus. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 28-39.	1.0	84
901	Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment. <i>Platelets</i> , 2015, 26, 783-787.	1.1	15
902	Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology. <i>Drugs</i> , 2015, 75, 859-877.	4.9	284
903	New insights into the use of currently available non-steroidal anti-inflammatory drugs. <i>Journal of Pain Research</i> , 2015, 8, 105.	0.8	291
904	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 96-106.	0.7	112
905	Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis. <i>European Journal of Cancer</i> , 2015, 51, 751-757.	1.3	8
906	Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 41-52.	1.5	11

#	ARTICLE	IF	CITATIONS
907	Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. Trends in Cardiovascular Medicine, 2015, 25, 726-735.	2.3	30
909	Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents. Drugs, 2015, 75, 1613-1625.	4.9	7
910	A tryptophan derivative TD-26 attenuates thrombus formation by inhibiting both PI3K/Akt signaling and binding of fibrinogen to integrin $\alpha\text{IIb}\beta\text{3}$. Biochemical and Biophysical Research Communications, 2015, 465, 516-522.	1.0	6
912	Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 422-432.	1.2	169
914	Do we need antiplatelet therapy in thrombocytosis? Contra. Hamostaseologie, 2016, 36, 241-260.	0.9	10
915	Monitoring the Antiplatelet Effect of Cilostazol with Light Transmission Aggregometer: Two Cases of Possible Cilostazol Resistance. Laboratory Medicine Online, 2016, 6, 214.	0.0	0
917	NSAID-induced Gastrointestinal Injury. Journal of Clinical Gastroenterology, 2016, 50, 5-10.	1.1	100
918	Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. Blood Coagulation and Fibrinolysis, 2016, 27, 169-175.	0.5	7
920	Non-steroidal anti-inflammatory drugs (NSAIDs). , 2016, , 236-272.		1
921	Anthocyanins in obesity-associated thrombogenesis: a review of the potential mechanism of action. Food and Function, 2016, 7, 2169-2178.	2.1	21
922	Pain management in critically ill patients: a review of multimodal treatment options. Pain Management, 2016, 6, 591-602.	0.7	12
923	Aspirin resistance in coronary heart disease: Current understandings and strategies. Journal of Translational Internal Medicine, 2016, 4, 7-10.	1.0	6
924	High-on-Aspirin Residual Platelet Reactivity Evaluated Using the Multiplate [®] Point-of-Care Device. Acta Marisiensis - Seria Medica, 2016, 62, 101-105.	0.3	0
925	Adverse Effects of NSAIDs in the Gastrointestinal Tract: Risk Factors of Gastrointestinal Toxicity with NSAIDs. , 2016, , 45-59.		1
926	NSAIDs and Aspirin: Recent Advances and Implications for Clinical Management. , 2016, , 107-122.		3
928	Comparing light transmission aggregometry and PFA100 for monitoring antiplatelet therapy in patients with coronary heart disease. Journal of Taibah University Medical Sciences, 2016, 11, 478-484.	0.5	1
929	The Clinical Diagnosis and Management of Kawasaki Disease: a Review and Update. Current Infectious Disease Reports, 2016, 18, 32.	1.3	35
930	Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation, 2016, 134, 1579-1594.	1.6	107

#	ARTICLE	IF	CITATIONS
931	NSAIDs and Aspirin. , 2016, , .		6
932	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. <i>New England Journal of Medicine</i> , 2016, 375, 2519-2529.	13.9	607
933	Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease. <i>Clinical Proteomics</i> , 2016, 13, 20.	1.1	18
934	Pharmacotherapy With Antiplatelet, Anticoagulant, and Their Reversing Agents. , 2016, , 39-72.		1
935	Aspirin, stroke and drug-drug interactions. <i>Vascular Pharmacology</i> , 2016, 87, 14-22.	1.0	23
936	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
939	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 108-118.	1.4	35
940	Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. <i>Thrombosis Research</i> , 2016, 142, 26-32.	0.8	9
941	Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome. <i>The Cochrane Library</i> , 0, , .	1.5	4
942	Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 316-326.	1.1	8
943	Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 447-455.	1.0	20
945	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. <i>Pharmacological Research</i> , 2016, 103, 132-143.	3.1	10
946	Fatal Thrombosis of a Flow Diverter due to Ibuprofen-related Antagonization of Acetylsalicylic Acid. <i>Clinical Neuroradiology</i> , 2016, 26, 355-358.	1.0	11
947	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 1015-1023.	1.0	109
948	Long-term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325mg and Immediate-Release Omeprazole 40mg for Secondary Cardiovascular Disease Prevention in Patients at <sc>GI</sc> Risk. <i>Cardiovascular Therapeutics</i> , 2016, 34, 59-66.	1.1	6
949	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2016, , 992-1013.		0
950	Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs. <i>Current Cardiology Reports</i> , 2016, 18, 25.	1.3	36
951	Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects. <i>Journal of the American Dental Association</i> , 2016, 147, 98-110.	0.7	35

#	ARTICLE	IF	CITATIONS
952	Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets. <i>Vascular Pharmacology</i> , 2016, 76, 11-17.	1.0	19
953	Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009-2010. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 243-249.	1.0	13
954	Evening primrose oil or forskolin ameliorates celecoxib-enhanced upregulation of tissue factor expression in mice subjected to lipopolysaccharide-induced endotoxemia. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 483-492.	1.4	5
955	Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial. <i>Journal of International Medical Research</i> , 2017, 45, 59-74.	0.4	28
956	Analgesic medication with dipyron in patients with coronary artery disease: Relation to MACCE. <i>International Journal of Cardiology</i> , 2017, 236, 76-81.	0.8	22
957	Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Aspirin: A Case-crossover Study and a Propensity Score-matched Cohort Study. <i>Journal of Rheumatology</i> , 2017, 44, 418-424.	1.0	8
958	Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review. <i>Current Cardiology Reports</i> , 2017, 19, 18.	1.3	6
959	Additive antithrombotic effect of ASP6537, a selective cyclooxygenase (COX)-1 inhibitor, in combination with clopidogrel in guinea pigs. <i>European Journal of Pharmacology</i> , 2017, 798, 72-76.	1.7	4
960	Dipyron (metamizole) markedly interferes with platelet inhibition by aspirin in patients with acute and chronic pain. <i>European Journal of Anaesthesiology</i> , 2017, 34, 288-296.	0.7	9
961	Establishment of reference ranges and evaluation of <i>in vitro</i> concentration-dependent platelet inhibition by acetylsalicylic acid for multiple electrode impedance aggregometry in healthy dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 618-628.	0.6	5
962	Pharmacogenomics of Antiplatelet Drugs. , 2017, , 1325-1340.		0
963	Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months. <i>Paediatric Drugs</i> , 2017, 19, 277-290.	1.3	26
964	Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: Immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2. <i>Chemico-Biological Interactions</i> , 2017, 272, 92-106.	1.7	13
965	The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 733-748.	4.0	125
966	Nonsteroidal anti-inflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 791-807.	1.0	50
967	How I use laboratory monitoring of antiplatelet therapy. <i>Blood</i> , 2017, 130, 713-721.	0.6	42
968	NSAIDs and cardiovascular risk. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e40-e43.	0.6	69
969	Prostanoids in the pathophysiology of human coronary artery. <i>Prostaglandins and Other Lipid Mediators</i> , 2017, 133, 20-28.	1.0	19

#	ARTICLE	IF	CITATIONS
970	Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. <i>Circulation</i> , 2017, 135, e927-e999.	1.6	2,406
971	Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 9.	0.4	10
972	Mildly elevated unconjugated bilirubin is associated with reduced platelet activation-related thrombogenesis and inflammation in Gilbert's syndrome. <i>Platelets</i> , 2017, 28, 779-785.	1.1	19
973	Antiplatelet agents in hemodialysis. <i>Journal of Nephrology</i> , 2017, 30, 373-383.	0.9	9
974	Abordaje multifactorial del dolor crónico no neoplásico en Atención Primaria. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2017, 24, 1-55.	0.0	0
975	Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors. <i>Journal of Orthopaedics</i> , 2017, 14, 537-543.	0.6	29
976	Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality. <i>Open Heart</i> , 2017, 4, e000642.	0.9	2
977	The evolution of the Helsinki frostbite management protocol. <i>Burns</i> , 2017, 43, 1455-1463.	1.1	44
978	Essential Thrombocytosis and Labor Epidural Placement While on Aspirin. <i>A & A Case Reports</i> , 2017, 9, 172-174.	0.7	2
979	Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?. <i>Modern Rheumatology</i> , 2017, 27, 559-569.	0.9	19
982	The dawn of neurosurgery in pre-conquest Mesoamerican territories. <i>Child's Nervous System</i> , 2017, 33, 1621-1629.	0.6	3
983	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition). <i>Regional Anesthesia and Pain Medicine</i> , 2017, 43, 1.	1.1	117
984	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. , 2017, , 617-643.		1
985	Antiplatelet treatment in the primary prophylaxis of cardiovascular disease in patients with arterial hypertension. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2017, 2, 133-136.	0.1	2
986	Clinical Uses of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Potential Benefits of NSAIDs Modified-Release Preparations. , 2017, , 1-29.		13
987	The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. <i>Rheumatology</i> , 2018, 57, 1364-1369.	0.9	3
988	The Aspirin-NSAID Interaction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1752-1754.	1.2	10
989	Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in High-Risk Patients for Cardiovascular Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 111-119.	2.3	7

#	ARTICLE	IF	CITATIONS
990	Cardiorenal Safety of OTC Analgesics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 103-118.	1.0	18
991	Chronic Mild Hyperhomocysteinemia Alters Inflammatory and Oxidative/Nitrative Status and Causes Protein/DNA Damage, as well as Ultrastructural Changes in Cerebral Cortex: Is Acetylsalicylic Acid Neuroprotective?. <i>Neurotoxicity Research</i> , 2018, 33, 580-592.	1.3	16
992	Comprehensive review of cardiovascular toxicity of drugs and related agents. <i>Medicinal Research Reviews</i> , 2018, 38, 1332-1403.	5.0	176
993	Drug-Drug Interactions as a Complication of Maxillofacial Surgery. , 2018, , 643-659.		0
994	The Prevalence and Clinical Relevance of ASA Nonresponse After Cardiac Surgery: A Prospective Bicentric Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 179-185.	0.7	5
995	PLGA with less than 1 month of half-life time: Tensile properties in dry and wet states and hydrolytic degradation. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2018, 67, 509-516.	1.8	7
996	The effects of Î²-d-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line. <i>Inflammopharmacology</i> , 2018, 26, 375-384.	1.9	10
997	Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?. <i>Diabetes and Metabolism</i> , 2018, 44, 217-225.	1.4	13
998	Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support. <i>Thrombosis Research</i> , 2018, 163, 162-171.	0.8	15
999	Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. <i>Postgraduate Medicine</i> , 2018, 130, 55-71.	0.9	46
1000	Effect of Aspirin and ibuprofen either alone or in combination on gastric mucosa and bleeding time and on serum prostaglandin E2 and thromboxane A2 levels in the anaesthetized rats in vivo. <i>Molecular and Cellular Biochemistry</i> , 2018, 438, 25-34.	1.4	12
1001	Analgetika und Koanalgetika in der Schmerzmedizin. <i>Springer Reference Medizin</i> , 2018, , 1-41.	0.0	0
1003	The Clinical Efficacy and Safety of Gumiganghwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-8.	0.5	5
1004	Differential compensation of two cyclooxygenases in renal homeostasis is independent of prostaglandin-synthetic capacity under basal conditions. <i>FASEB Journal</i> , 2018, 32, 5326-5337.	0.2	4
1005	Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis. <i>Ageing Research Reviews</i> , 2018, 48, 51-78.	5.0	23
1006	Diabetes and Platelet Response to Low-dose Aspirin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4599-4608.	1.8	8
1007	Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	7
1008	Antiplatelet Effect of Ketorolac in Children After Congenital Cardiac Surgery. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2018, 9, 651-658.	0.3	5

#	ARTICLE	IF	CITATIONS
1009	Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample. <i>Drug Safety</i> , 2018, 41, 1049-1058.	1.4	10
1010	Drugs Used in Rheumatic Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, 15, 39-76.	0.1	2
1011	Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose. <i>Current Treatment Options in Neurology</i> , 2018, 20, 32.	0.7	4
1012	Acquired Disorders of Platelet Function. , 2018, , 1932-1943.e6.		1
1013	Aspirin Resistance and Stroke. <i>Journal of Stroke Medicine</i> , 2018, 1, 19-27.	0.2	7
1014	Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti-Inflammatory Drugs: A Systematic Review. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 48s-73s.	0.9	15
1015	Safety Considerations in Prescription of NSAIDs for Musculoskeletal Pain: A Narrative Review. <i>PM and R</i> , 2018, 10, 1404-1411.	0.9	15
1016	Studying additive interaction in a healthcare database: Case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction. <i>PLoS ONE</i> , 2018, 13, e0201884.	1.1	5
1017	Time to stroke: A Western Trauma Association multicenter study of blunt cerebrovascular injuries. <i>Journal of Trauma and Acute Care Surgery</i> , 2018, 85, 858-866.	1.1	52
1018	Polypharmacy and Rational Prescribing: Changing the Culture of Medicine One Patient at a Time. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2019, 7, 141-158.	0.3	4
1019	Pharmacodynamic effects of Dan-hong injection in rats with blood stasis syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109187.	2.5	19
1020	Kawasaki disease in 2019â€”past controversies, present insights and future directions. <i>Pediatric Medicine</i> , 2019, 2, 10-10.	1.1	3
1021	Overproduction of thrombopoietin by BRAFV600Eâ€”mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis. <i>Cancer Science</i> , 2019, 110, 2748-2759.	1.7	3
1022	Pharmacoepidemiology of non-steroidal anti-inflammatory drugs. <i>Therapie</i> , 2019, 74, 271-277.	0.6	42
1023	Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus. <i>Advances in Therapy</i> , 2019, 36, 2618-2637.	1.3	53
1024	Platelet function testing in pigs using the MultiplateÂ® Analyzer. <i>PLoS ONE</i> , 2019, 14, e0222010.	1.1	7
1025	Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2019, 50, e51-e96.	1.0	425
1026	Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108906.	2.5	9

#	ARTICLE	IF	CITATIONS
1027	Nonsteroidal Anti-Inflammatory Drugs. , 2019, , 237-243.		0
1028	Intercalation of manganese-mefenamic acid complex into double stranded of calf thymus DNA. Nucleosides, Nucleotides and Nucleic Acids, 2019, 38, 901-919.	0.4	4
1029	Pharmacodynamic Drug-Drug Interactions. Clinical Pharmacology and Therapeutics, 2019, 105, 1395-1406.	2.3	101
1030	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
1032	Encapsulation of Aspirin into parent and functionalized MCM-41, in vitro release as well as kinetics. Journal of Porous Materials, 2019, 26, 1523-1532.	1.3	6
1033	No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes using non-steroidal anti-inflammatory drugs. Diabetes, Obesity and Metabolism, 2019, 21, 1978-1984.	2.2	4
1034	Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion. Advances in Pharmacological Sciences, 2019, 2019, 1-10.	3.7	93
1035	Spinal Imaging, Stability and Management of Spine Pain due to Cancer. , 2019, , 133-152.		0
1036	A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety. European Journal of Pharmaceutical Sciences, 2019, 131, 159-166.	1.9	6
1037	Efficacy of dual antiplatelet therapy as premedication before diagnostic cerebral digital subtraction angiography. Journal of Cerebrovascular and Endovascular Neurosurgery, 2019, 21, 131.	0.2	0
1039	A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. Journal of Thrombosis and Thrombolysis, 2019, 47, 16-30.	1.0	22
1040	Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: A natural cargo. International Journal of Biological Macromolecules, 2019, 123, 979-990.	3.6	300
1041	Pharmacologic Interactions. , 2019, , 432-445.e7.		0
1042	Investigation into the causes of aspirin resistance in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics, 2019, 42, 160-170.	0.6	3
1043	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology, 2019, 58, 672-682.	0.9	103
1044	Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyron co-medicated chronic artery disease patients. European Journal of Clinical Pharmacology, 2019, 75, 13-20.	0.8	12
1045	Antimicrobial Peptide Cathelicidin-BF Inhibits Platelet Aggregation by Blocking Protease-Activated Receptor 4. International Journal of Peptide Research and Therapeutics, 2019, 25, 349-358.	0.9	8
1046	Qualitative disorders of platelets and vasculature. , 2020, , 675-694.		0

#	ARTICLE	IF	CITATIONS
1047	Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. <i>Pharmacology</i> , 2020, 105, 118-122.	0.9	7
1048	Antiplatelet agents: past, present and future. <i>ISBT Science Series</i> , 2020, 15, 131-141.	1.1	9
1049	Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update. <i>Drug Safety</i> , 2020, 43, 301-318.	1.4	35
1050	Synthesis, pharmacological evaluation and molecular docking of novel R/S-2-(2-hydroxypropanamido)-5-trifluoromethyl benzoic acid as dual anti-inflammatory anti-platelet aggregation agents. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 967-978.	1.4	2
1051	Monitoring Commercial Ibuprofen Potency Changes Over 1 Year When Stored in a Household Setting. <i>Journal of Pharmacy Technology</i> , 2020, 36, 16-21.	0.5	1
1052	Combining acetyl salicylic acid and rofecoxib into novel oral tablets normalize platelet function with potential higher tolerability in patients with cardiovascular disorders. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 59, 101851.	1.4	3
1053	Aspirin in ET: will twice a day keep thrombosis away?. <i>Blood</i> , 2020, 136, 151-153.	0.6	1
1054	A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 194-211.	2.9	250
1055	Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 518-529.	1.2	21
1056	Antiplatelet Therapy after Coronary Artery Bypass Graft Surgery, Inconsistency of Clinical Practice and Clinical Significance of Proven Resistance to Antiplatelet Agents. , 0, , .		0
1057	The Importance of Breast Adipose Tissue in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5760.	1.8	82
1058	Acquired bleeding disorders through antithrombotic therapy: the implications for dental practitioners. <i>British Dental Journal</i> , 2020, 229, 729-734.	0.3	1
1059	Lessons Learned: Using the Caprini Risk Assessment Model to Provide Safe and Efficacious Thromboprophylaxis Following Hip and Knee Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096145.	0.7	8
1060	Interaction Between Low-Dose Aspirin and Nonsteroidal Anti-Inflammatory Drugs Can Compromise Aspirin's Efficacy in Preventing Venous Thrombosis Following Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962092037.	0.7	7
1061	Synthesis, Stability, and Biological Studies of Fluorinated Analogues of Thromboxane A ₂ . <i>ACS Central Science</i> , 2020, 6, 995-1000.	5.3	9
1062	Structural modification of aspirin to design a new potential cyclooxygenase (COX-2) inhibitors. In <i>Silico Pharmacology</i> , 2020, 8, 1.	1.8	25
1063	Misguided drug advice for COVID-19. <i>Science</i> , 2020, 367, 1434-1434.	6.0	139
1064	Treatment of blunt cerebrovascular injuries: Anticoagulants or antiplatelet agents?. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, 74-79.	1.1	18

#	ARTICLE	IF	CITATIONS
1065	Biological Evaluation of Naproxenâ€‘Dehydrodipeptide Conjugates with Self-Hydrogelation Capacity as Dual LOX/COX Inhibitors. <i>Pharmaceutics</i> , 2020, 12, 122.	2.0	16
1066	Indications and Evidence for Dual Antiplatelet Therapy After Acute Ischemic Stroke. <i>Critical Care Nursing Quarterly</i> , 2020, 43, 122-137.	0.4	5
1068	Not all (N)SAID and done: Effects of nonsteroidal antiâ€‘inflammatory drugs and paracetamol intake on platelets. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 36-45.	1.0	15
1069	The emergent phenomenon of aspirin resistance: insights from genetic association studies. <i>Pharmacogenomics</i> , 2020, 21, 125-140.	0.6	19
1070	Safety of Ibuprofen in Patients With COVID-19. <i>Chest</i> , 2020, 158, 55-56.	0.4	74
1071	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020, 111, 102468.	3.0	103
1072	Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. <i>Platelets</i> , 2021, 32, 391-397.	1.1	10
1073	Cardiovascular risk of nonsteroidal anti-inflammatory drugs in dialysis patients: a nationwide population-based study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 909-917.	0.4	6
1074	ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 517-526.	0.8	2
1075	What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review. <i>Journal of Dental Sciences</i> , 2021, 16, 806-816.	1.2	11
1077	Pharmacodynamics and Pharmacokinetics of Stroke Therapy. , 2021, , 41-69.		0
1079	Pharmacotherapy in Systemic Rheumatic Diseases. , 2021, , 83-104.		2
1080	Kawasaki-Erkrankung. <i>Springer Reference Medizin</i> , 2021, , 1-19.	0.0	0
1081	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 629933.	1.1	43
1082	Oral administration of hydrolysates of cartilage extract in the prevention of osteoarthritis. <i>Journal of Functional Foods</i> , 2021, 78, 104376.	1.6	11
1083	Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why?. <i>American Journal of Cardiology</i> , 2021, 144, S10-S14.	0.7	1
1084	Overview of Aspirin and Platelet Biology. <i>American Journal of Cardiology</i> , 2021, 144, S2-S9.	0.7	22
1086	In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. <i>Scientific Reports</i> , 2021, 11, 10370.	1.6	8

#	ARTICLE	IF	CITATIONS
1087	Paracetamol Intake and Hematologic Malignancies: A Meta-Analysis of Observational Studies. <i>Journal of Clinical Medicine</i> , 2021, 10, 2429.	1.0	0
1088	Cardiovascular Risk in Rheumatoid Arthritis: Literature Review. <i>Oman Medical Journal</i> , 2021, 36, e262-e262.	0.3	4
1090	Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 684162.	1.6	30
1092	Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 800-814.	1.5	12
1093	Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review. <i>Frontiers in Neurology</i> , 2021, 12, 667234.	1.1	8
1094	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2835.	1.0	5
1095	Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6637.	1.8	18
1098	Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10581-10605.	2.9	56
1099	Coronary artery ectasia in postâ€pericardiotomy syndrome. <i>Echocardiography</i> , 2021, 38, 1678-1683.	0.3	0
1100	Salicylic acid-based nanomedicine with self-immunomodulatory activity facilitates microRNA therapy for metabolic skeletal disorders. <i>Acta Biomaterialia</i> , 2021, 130, 435-446.	4.1	10
1101	Perioperative Antiplatelet and Anticoagulant Management with Endodontic Microsurgical Techniques. <i>Journal of Endodontics</i> , 2021, 47, 1557-1565.	1.4	1
1102	Antiplatelet Therapy for Secondary Prevention of Stroke. , 2022, , 912-931.e4.		1
1103	Choice of optimal non-steroidal anti-inflammatory drug from position of cardiologist. <i>Medical Alphabet</i> , 2021, , 55-60.	0.0	1
1105	Arthritis Medications and Cardiovascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1975.	3.8	1
1107	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction. , 0, , 397-425.		2
1110	Eicosanoids and the Vascular Endothelium. , 2006, , 189-211.		34
1111	Nonsteroidal Anti-Inflammatory Drugs. , 2008, , 634-643.		1
1112	Resistance to Antiplatelet Drugs. , 2010, , 449-464.		1

#	ARTICLE	IF	CITATIONS
1113	Aspirin in Primary and Secondary Prevention of Cardiovascular Disease. , 2010, , 117-129.		1
1114	Treatment of Acute ST-Elevation Myocardial Infarction. , 2007, , 963-977.		1
1116	Antiaggregatorische Therapie. , 2010, , 795-800.		2
1118	Anti-Inflammatory Therapeutic Approaches. , 2012, , 513-528.		1
1119	Propionic Acid Derivative Drugs (Profens). , 2016, , 1106-1110.		1
1120	Non-steroidal anti-inflammatory drugs. , 2011, , 485-493.		2
1121	Anti-inflammatory and immunosuppressant drugs. , 2007, , 226-247.		8
1122	Pharmacologic Management of the Orthopaedic Trauma Patient. , 2009, , 253-285.		1
1123	Nonsteroidal Anti-inflammatory Drugs. , 2009, , 833-861.		3
1126	Oral antiplatelet agents in cardiovascular disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 291-302.	0.6	14
1128	Using NSAIDs in cardiovascular disease. Drug and Therapeutics Bulletin, 2010, 48, 26-29.	0.3	15
1130	Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. Journal of Clinical Investigation, 2005, 115, 986-995.	3.9	64
1131	Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. Journal of Clinical Investigation, 2006, 116, 1391-1399.	3.9	313
1132	Signaling Pathways Involved in Sphingosine Kinase Activation and Sphingosine-1-Phosphate Release in Rat Myometrium in Late Pregnancy: Role in the Induction of Cyclooxygenase 2. Endocrinology, 2008, 149, 4669-4679.	1.4	20
1133	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circulation Journal, 2019, 83, 1085-1196.	0.7	324
1134	In Vitro Inflammation Inhibition Model Based on Semi-Continuous Toll-Like Receptor Biosensing. PLoS ONE, 2014, 9, e105212.	1.1	9
1135	High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction. Anatolian Journal of Cardiology, 2017, 17, 113-118.	0.5	9
1136	Topical diclofenac for the treatment of the musculoskeletal diseases. Meditsinskiy Sovet, 2018, , 98-104.	0.1	2

#	ARTICLE	IF	CITATIONS
1138	Aspirin and Antiplatelet Agent Resistance. <i>CNS Drugs</i> , 2010, , 1.	2.7	8
1139	Therapy Against Ischemic Injury. <i>Current Pharmaceutical Design</i> , 2013, 19, 4597-4621.	0.9	6
1140	Genetic Signatures in the Treatment of Stroke. <i>Current Pharmaceutical Design</i> , 2014, 21, 343-354.	0.9	5
1141	Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2007, 7, 274-287.	0.2	10
1142	Cardiac toxicity of coxibs: mechanisms of development and their prevention. <i>Pain Medicine</i> , 2018, 3, 27-32.	0.1	2
1143	The prognostic utility of tests of platelet function for the detection of "aspirin resistance"™ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-366.	1.3	22
1144	Considering Cardiovascular Risks when Using NSAIDs. <i>Orthopedics</i> , 2008, 31, 468-471.	0.5	3
1145	COX-2-selective inhibitors in the treatment of arthritis.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, S120-S120.	0.6	23
1146	Variable response to antiplatelet therapy: what does it mean to clinicians?. <i>Cleveland Clinic Journal of Medicine</i> , 2007, 74, 49-55.	0.6	4
1147	Aspirin resistance and ischemic heart disease on Iranian experience. <i>Advanced Biomedical Research</i> , 2012, 1, 33.	0.2	4
1148	NSAIDs; Safety and Risk Assessment in CVS Events, Comparisons and Facts. <i>Journal of Bioequivalence & Bioavailability</i> , 2016, 08, .	0.1	2
1149	Aspirin resistance in young men with Type 2 diabetes. <i>Journal of Diabetes Mellitus</i> , 2014, 04, 72-76.	0.1	1
1150	Impairment of aspirin antiplatelet effects by non-opioid analgesic medication. <i>World Journal of Cardiology</i> , 2015, 7, 383.	0.5	17
1151	Selection of analgesics for the management of acute and postoperative dental pain: a mini-review. <i>Journal of Periodontal and Implant Science</i> , 2020, 50, 68.	0.9	13
1152	Aspirin resistance in patients with chronic renal failure. <i>Journal of Nephrology</i> , 2011, 24, 636-646.	0.9	33
1154	Influence of NSAIDs on Antiplatelet Effects of Aspirin-In vitro Experimental Study Involving NSAID Addition to Human Blood-. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and)</i> Tj ETQq1 1 0.7843 140gBT /Overlock 10		
1155	Influence of Loxoprofen Sodium on Antiplatelet Effect of Aspirin and How to Avoid this Interaction. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2011, 37, 69-77.	0.0	2
1156	The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors. <i>Annals of Internal Medicine</i> , 2005, 143, 616.	2.0	1

#	ARTICLE	IF	CITATIONS
1157	Prime Drug Interplay in Dental Practice. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, ZE07-11.	0.8	4
1159	Ibuprofen melts aspirin's heart. Nature, 0, , .	13.7	0
1160	Pharmacotherapy of Pain in Older Adults. , 2004, , 87-113.		0
1161	Tolerability of Rofecoxib versus Naproxen. Annals of Internal Medicine, 2004, 140, 1060.	2.0	1
1162	Detection and Management of Aspirin Resistance. Critical Pathways in Cardiology, 2004, 3, 177-183.	0.2	1
1163	Complications of the Medications. , 2005, , 6-16.		0
1164	Nonopioid Analgesics. , 2006, , 253-303.		0
1165	Cyclooxygenase (E.C. 1.14.99.1). British Journal of Pharmacology, 2006, , S157-S157.	2.7	1
1166	Anticoagulation and Antiplatelet Agents. Fundamental and Clinical Cardiology, 2006, , 501-524.	0.0	0
1168	Non-Steroidal Antiinflammatory Drug Gastroenteropathy. , 2007, , 1-10.		0
1170	Sodium Balance in Heart Failure. , 2007, , 351-364.		0
1172	Arzneimittelinteraktionen: eine aktuelle Auswahl. Pharma-Kritik (discontinued), 2008, 30, .	0.0	0
1173	Which Therapy for Which Condition?. , 2009, , 388-458.		1
1174	Aspirin Usage Based on Evidence for the Prevention of Cardio-Cerebrovascular Disease. Korean Journal of Family Medicine, 2009, 30, 249.	0.4	1
1175	Comparison and analysis of the effectiveness to high dose of aspirin and ibuprofen in acute phase of Kawasaki disease. Korean Journal of Pediatrics, 2009, 52, 930.	1.9	1
1177	Thrombosen und GefÄÄÿverschlÄÄÿsse trotz antithrombotischer Therapie. , 2010, , 681-688.		0
1182	Anesthetic Maintenance of Video-Assisted Endolaparoscopic Surgery for Female Infertility. Obshchaya Reanimatologiya, 2010, 6, 49.	0.2	0
1183	Clopidogrel and Salicylates. , 2011, , 139-153.		0

#	ARTICLE	IF	CITATIONS
1184	Aspirin resistance after coronary artery bypass grafting. <i>Cor Et Vasa</i> , 2010, 52, 52-58.	0.1	0
1185	Analgetika und Coanalgetika: Anwendung, gesetzliche Grundlagen und Probleme. , 2011, , 229-267.		0
1188	Dietary Intervention in Coronary Care Units and in Secondary Prevention. , 2011, , 344-360.		0
1189	NSAIDs and Peptic Ulcer Disease. , 0, , .		2
1190	The Clinical Relevance of Response Variability to Antiplatelet Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 70-75.	0.9	0
1191	The Role of Laboratory Monitoring in Antiplatelet Therapy. <i>Handbook of Experimental Pharmacology</i> , 2012, , 471-494.	0.9	2
1194	Analgetika. , 2013, , 1-69.		0
1195	Propionic Acid Derivative Drugs (Profens). , 2013, , 1-6.		0
1196	ASPIRIN RESISTANCE CANDIDATE GENES AND THEIR ASSOCIATION WITH THE RISK OF CARDIOVASCULAR EVENTS. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2013, 12, 67-72.	0.4	1
1197	Assessment of Bleeding Risk of Interventional Techniques: A Best Evidence Synthesis of Practice Patterns and Perioperative Management of Anticoagulant and Antithrombotic Therapy. <i>Pain Physician</i> , 2013, 2s;16, SE216-SE318.	0.3	11
1198	Analgetika und Koanalgetika in der. , 2014, , 1-55.		0
1200	Nonsteroidal antiinflammatory drugs. , 2015, , 415-422.		3
1203	Platelet Prostanoids and their receptors. , 2017, , 203-211.		1
1204	Interaction between Proton Pump Inhibitors and Antiplatelet Therapy. <i>The Egyptian Journal of Hospital Medicine</i> , 2017, 69, 2871-2875.	0.0	0
1205	Clinically important drug interactions with opioid and non-opioid analgesics. <i>Arhiv Za Farmaciju</i> , 2018, 68, 1071-1083.	0.2	0
1206	Frequency of development of aspirin resistance in the early postoperative period and inadequate inhibition of thromboxane A2 production after coronary artery bypass surgery. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 26, 536-543.	0.2	1
1207	Comparative Study between High Dose Aspirin and Ibuprofen in the Treatment of Kawasaki Disease in the Acute Stage. <i>Soonchunhyang Medical Science</i> , 2018, 24, 175-180.	0.0	0
1208	Nonsteroidal Anti-inflammatory Drugs. , 2019, , 689-707.		1

#	ARTICLE	IF	CITATIONS
1209	Tratamiento farmacológico de la enfermedad de Kawasaki. Revista Facultad De Medicina, 2019, 67, 103-108.	0.0	1
1210	Analgetika und Koanalgetika in der Schmerzmedizin. Springer Reference Medizin, 2019, , 131-170.	0.0	0
1211	Clinically important drug interactions with opioid and non-opioid analgesics. Arhiv Za Farmaciju, 2019, 69, 1071-1083.	0.2	0
1212	Antiplatelet Resistance in Patients with Atherosclerosis. Proceedings of the Latvian Academy of Sciences, 2019, 73, 373-378.	0.0	1
1213	Factors Influencing Aspirin Hyporesponsiveness in Elderly Chinese Patients. Medical Science Monitor, 2019, 25, 5191-5200.	0.5	0
1214	Antiplatelet Effect of a Pulaimab [Anti-GPIIb/IIIa F(ab)2 Injection] Evaluated by a Population Pharmacokinetic-pharmacodynamic Model. Current Drug Metabolism, 2020, 20, 1060-1072.	0.7	0
1216	Antiplatelet Therapy. Contemporary Cardiology, 2021, , 249-288.	0.0	0
1217	ACETYLSALICYLIC ACID RESISTANCE: RISK FACTORS, MECHANISMS, DIAGNOSTIC TESTS. Juvenis Scientia, 2020, 6, 16-34.	0.1	2
1218	Anticoagulants and Antiplatelet Drugs. , 2021, , .		0
1219	Patogênese e perspectivas de tratamento da Covid-19: uma revisão. Research, Society and Development, 2020, 9, e05973730.	0.0	9
1220	Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. Clinical Pharmacology and Therapeutics, 2022, 111, 939-949.	2.3	6
1222	Prostanoid Generation in Platelet Function. , 2005, , 267-281.		0
1223	Platelets and new antiplatelet drugs. Therapy: Open Access in Clinical Medicine, 2005, 2, 465-502.	0.2	0
1227	Etoricoxib for arthritis and pain management. Therapeutics and Clinical Risk Management, 2006, 2, 45-57.	0.9	17
1229	Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. Canadian Family Physician, 2007, 53, 1177-84.	0.1	19
1230	Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease. Journal of the National Medical Association, 2006, 98, 1126-35.	0.6	4
1231	Aspirin resistance: A fact or a myth?. Experimental and Clinical Cardiology, 2005, 10, 17-20.	1.3	4
1232	Taking the stress out of managing gout. Canadian Family Physician, 2009, 55, 1209-12.	0.1	3

#	ARTICLE	IF	CITATIONS
1233	Pain management for dentists: the role of ibuprofen. <i>Annali Di Stomatologia</i> , 2011, 2, 3-24.	0.6	27
1234	A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass. <i>Journal of Extra-Corporeal Technology</i> , 2010, 42, 103-13.	0.2	0
1235	Cox-2 inhibitors in mandibular third molar surgery. <i>Journal of Medicine and Life</i> , 2019, 12, 150-155.	0.4	1
1236	Hematoma and Thromboprophylaxis. , 2022, , 297-302.		0
1237	Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	6
1239	Evaluation of the Role of Antiplatelet Medications in Cardiovascular Disease. <i>Pharmacophore</i> , 2021, 12, 97-103.	0.2	3
1240	Progress of Coronary Artery Lesions in Kawasaki Disease. <i>Advances in Clinical Medicine</i> , 2022, 12, 579-586.	0.0	0
1241	High on-treatment platelet reactivity to aspirin in patients after myocardial infarction. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112618.	2.5	4
1242	Identification and function analysis of BmPxtA in the immune response regulated by PGE2 of silkworm, <i>Bombyx mori</i> . <i>Developmental and Comparative Immunology</i> , 2022, 130, 104358.	1.0	2
1244	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13079.	1.8	20
1245	Over-the-counter and under the radar: Improving safety and effectiveness of nonprescription analgesics. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, , .	0.7	0
1246	Gaultherin production from gandapura (<i>Gandapura fragantissima</i>) using photo extractor-UV machine. <i>Materials Today: Proceedings</i> , 2022, , .	0.9	0
1247	Herbâ€Drug Interaction in Inflammatory Diseases: Review of Phytochemistry and Herbal Supplements. <i>Journal of Clinical Medicine</i> , 2022, 11, 1567.	1.0	7
1248	Recommendations from the ICM-VTE: General. <i>Journal of Bone and Joint Surgery - Series A</i> , 2022, 104, 4-162.	1.4	14
1249	Which NSAID to choose for treatment of pain syndrome in polymorbid patients?. <i>Medical Alphabet</i> , 2021, , 41-46.	0.0	0
1250	The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study. <i>Drugs and Aging</i> , 2022, 39, 97-106.	1.3	1
1251	Pharmacist intervention and <sc>antiâ€platelet</sc> medication monitoring in patients following stroke and transient ischemic attack. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 311-317.	0.5	0
1254	Cox-2 inhibitors in mandibular third molar surgery. <i>Journal of Medicine and Life</i> , 2019, 12, 150-155.	0.4	2

#	ARTICLE	IF	CITATIONS
1255	Which therapy for which condition?. , 2013, , 463-541.		1
1258	Knowledge and Awareness regarding Dental Management of Hemophilic Patients among Students of a Malaysian University: A Cross-Sectional Study. Open Dentistry Journal, 2022, 16, .	0.2	1
1259	Impact of the <i>PEAR</i> <i>1</i> polymorphism on clinical outcomes in Chinese patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Pharmacogenomics, 2022, 23, 639-648.	0.6	2
1260	Perioperative Management of Antithrombotic Therapy. Chest, 2022, 162, e207-e243.	0.4	81
1261	Kawasaki Disease and Coronary Artery Involvement: A Narrative Review. Cureus, 2022, , .	0.2	4
1262	Acetaminophen, Nonsteroidal Anti-Inflammatory Drugs, and Hypertension. Hypertension, 2022, 79, 1922-1926.	1.3	14
1263	Clinical pharmacology of antiplatelet drugs. Expert Review of Clinical Pharmacology, 2022, 15, 1177-1197.	1.3	14
1264	Utility of constraints reflecting system stability on analyses for biological models. PLoS Computational Biology, 2022, 18, e1010441.	1.5	1
1266	Pollen-derived microcapsules for aspirin microencapsulation: <i>in vitro</i> release and physico-chemical studies. RSC Advances, 2022, 12, 22139-22149.	1.7	5
1267	Nonsteroidal Anti-inflammatory Drugs Are Not Associated With Increased Bleeding in Blunt Solid Organ Injury. Journal of Trauma Nursing: the Official Journal of the Society of Trauma Nurses, 2022, 29, 235-239.	0.3	0
1268	Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. Paediatric Drugs, 2022, 24, 603-655.	1.3	14
1269	Comparative Risks of Nonsteroidal Anti-inflammatory Drugs on Cardiovascular Diseases: A Population-Based Cohort Study. Journal of Clinical Pharmacology, 2023, 63, 126-134.	1.0	2
1270	Fifty years with aspirin and platelets. British Journal of Pharmacology, 2023, 180, 25-43.	2.7	12
1271	Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nature Reviews Immunology, 2023, 23, 274-288.	10.6	75
1272	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. Frontiers in Pharmacology, 0, 13, .	1.6	8
1273	COX-2 selective inhibitors - they are still the best treatment for many patients!. Swiss Medical Weekly, 0, , .	0.8	2
1274	The COX-2 inhibitors: a reasoned review of the data. Swiss Medical Weekly, 0, , .	0.8	2
1275	Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?. Molecules, 2022, 27, 8919.	1.7	2

#	ARTICLE	IF	CITATIONS
1278	Propionic Acid Derivative Drugs (Profens). , 2016, , 1-6.		0
1279	New Advances in the Management of Endodontic Pa in Emergencies. Journal of the California Dental Association, 2004, 32, 469-473.	0.0	13
1280	Monitoring antiplatelet therapy: where are we now?. Journal of Cardiovascular Medicine, 2023, 24, e24-e35.	0.6	4
1281	Modulatory Effect of Lifestyle-Related, Environmental and Genetic Factors on Paraoxonase-1 Activity: A Review. International Journal of Environmental Research and Public Health, 2023, 20, 2813.	1.2	4
1282	Editor's Choice â€“ European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. European Journal of Vascular and Endovascular Surgery, 2023, 65, 627-689.	0.8	29
1283	Spider diagram and sustainability evaluation of UV-methods strategy for quantification of aspirin and sildenafil citrate in the presence of salicylic acid in their bulk and formulation. Heliyon, 2023, 9, e15260.	1.4	9
1284	Strategies for Avoiding Typical Drugâ€™Drug Interactions and Drug-Related Problems in Patients with Vascular Diseases. Medicina (Lithuania), 2023, 59, 780.	0.8	0
1285	Non-steroidal anti-inflammatory drugs-aspirin interactions and with risk of cardiovascular disease in patients osteoarthritis. American Journal of Epidemiology, 0, , .	1.6	2
1286	Provider-directed analgesia for dental pain. Expert Review of Clinical Pharmacology, 2023, 16, 435-451.	1.3	0
1293	Recent advances in the role of neutrophils and neutrophil extracellular traps in acute pancreatitis. Clinical and Experimental Medicine, 2023, 23, 4107-4122.	1.9	1
1301	Pharmacogenetics and Pharmacogenomics Impact on Aspirin Response. , 0, , .		0